app,product,nmeIngredients,unii,therapeuticClass,substanceClass,moleculeType,specificType,appType,appRef,indDate,indDateNote,indDateRef,appSubmittedDate,appSubmittedDateRef,appApprovalDate,daysInClinicalDevelopment,daysInReview,first,orphan,fastTrack,breakthrough,priority,accelerated,nonFirstCycle,blackBox,diagnosticImaging,animalRule,SMILES,logP,innovation,disease,pharmacology,target,indication,crlRef
213006,Gemtesa,vibegron,M5TSE03W5U,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213006,1/29/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000MedR.pdf,12/26/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/23/2020,3981,363,,,,,,,,,,,O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5,2.31159788,,overactive bladder,Agonist,β3-adrenoceptor agonist,Treatment of overactive bladder,
761172,Ebanga,ansuvimab,TG8IQ19NG2,Antiviral,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761172,1/25/2018,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761172Orig1s000IntegratedR.pdf,5/29/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/21/2020,1061,206,,1,,1,1,,,,,,,,,ebola virus,Binding agent,Ebola glycoprotein-directed mAb,To treat Ebola virus,
214621,Orgovyx,relugolix,P76B05O5V6,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214621,12/1/2007,,https://www.sec.gov/Archives/edgar/data/1679082/000095012316018298/filename1.htm,4/20/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/18/2020,4766,242,,,,,1,,,,,,CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5,3.94109731,,prostate cancer,Antagonist,GnRH receptor antagonist,Advanced prostate cancer,
761150,Margenza,margetuximab,K911R84KEW,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150,8/1/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761150Orig1s000MultidisciplineR.pdf,12/18/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/16/2020,3790,364,,,1,,,,,1,,,,,,HER2-positive breast cancer,Binding agent,HER2-directed mAb,Metastatic HER2-positive breast cancer,
213189,Klisyri,tirbanibulin,4V9848RS5G,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213189,7/31/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213189Orig1s000MultidisciplineR.pdf,12/30/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/14/2020,2328,350,1,,,,,,,,,,C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4,3.2331649,,actinic keratosis,Inhibitor,Microtubule inhibitor,Actinic keratosis of the face or scalp,
214094,Orladeyo,berotralstat,XZA0KB1BDQ,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214094,5/1/2015,,https://clinicaltrials.gov/ct2/show/NCT02448264,12/3/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/3/2020,2043,366,,1,1,,,,,,,,C1CC1CNC(C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N,5.55719507,,hereditary angioedema,Inhibitor,Plasma kallikrein inhibitor,Prophylaxis for attacks of hereditary angioedema,
212642,gallium Ga 68 PSMA-11,gallium Ga 68 PSMA-11,ZJ0EKR6M10,Oncology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212642,8/24/2015,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212642Orig1s000MutlidisciplineR.pdf,9/6/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/1/2020,1926,452,1,,,,,,,,1,,,,,"imaging, prostate cancer",,Radioactive diagnostic,Diagnostic imaging agent for certain lesions in men with prostate cancer,
213793,Imcivree,setmelanotide,N7T15V1FUY,Endocrinology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213793,10/12/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000MedR.pdf,3/27/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/25/2020,3332,243,1,1,,1,1,,,,,,,,,proopiomelanocortin deficiency,Agonist,MC4 receptor agonist,To treat obesity and the control of hunger associated with specific enzyme deficiencies including proopiomelanocortin deficiency,
761171,Danyelza,naxitamab,9K8GNJ2874,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761171,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000MultidisciplineR.pdf,3/31/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/25/2020,NA,239,,1,,1,1,1,,1,,,,,,neuroblastoma,Binding agent,GD2-directed mAb,To treat refractory or relapsed high-risk neuroblastoma,
214103,Oxlumo,lumasiran,RZT8C352O1,Endocrinology,oligonucleotide,oligo,siRNA,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214103,3/8/2016,,https://clinicaltrials.gov/ct2/show/NCT02706886,4/3/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/23/2020,1721,234,1,1,,1,1,,,,,,,,,hyperoxaluria type 1,,HAO1-directed siRNA,To treat primary hyperoxaluria type 1,
213969,Zokinvy,lonafarnib,IOW153004F,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213969,12/1/1997,,https://link.springer.com/article/10.1007/s00280-010-1488-5,3/20/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/20/2020,8390,245,1,1,,1,1,,,,,,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1,4.62752386,,Hutchinson-Gilford progeria syndrome,Inhibitor,Farnesyltransferase inhibitor,To reduce the risk of death due to rare genetic diseases that cause premature aging,
214787,Veklury,remdesivir,3QKI37EEHE,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214787,7/1/2015,,https://www.gilead.com/-/media/gilead-corporate/files/pdfs/covid-19/gilead_rdv-development-fact-sheet-2020.pdf,8/7/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/22/2020,1940,76,1,,1,,1,,,,,,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,1.93573138,Fastest review time (76 days) for a non-accelerated approval,COVID-19,Inhibitor,Nucleotide analogue RNA polymerase inhibitor,To treat COVID-19,
761169,Inmazeb,atoltivimab|maftivimab|odesivimab,FJZ07Q63VY|KOP95331M4|UY9LQ8P6HW,Antiviral,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761169,5/27/2016,,https://clinicaltrials.gov/ct2/show/NCT02777151,2/25/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/14/2020,1601,232,1,1,,1,1,,,,,,,,,ebola virus,Binding agent,Cocktail of Ebola glycoprotein-directed mAbs,To treat Ebola virus,
213721,Gavreto,pralsetinib,1WPE73O1WV,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213721,3/17/2017,,https://clinicaltrials.gov/ct2/show/NCT03037385,3/23/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/4/2020,1267,165,,1,,1,1,1,,,,,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC,3.65427062,,non-small cell lung cancer,Inhibitor,RET kinase inhibitor,To treat non-small lung cancer,
213227,Detectnet,copper Cu 64 dotatate,N3858377KC,Oncology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213227,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213227Orig1s000MultidisciplineR.pdf,1/3/2020,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/3/2020,NA,244,,1,1,,1,,,,1,,,,,"imaging, cancer",,Radioactive diagnostic,Diagnostic imaging agent for certain types of neuroendocrine tumors,
761156,Sogroya,somapacitan,8FOJ430U94,Endocrinology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156,7/23/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761156Orig1s000MedR.pdf,8/28/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/28/2020,2228,366,,,,,,,,,,,,,,growth hormone deficiency,Agonist,Growth hormone analogue,Growth hormone deficiency,
213433,Winlevi,clascoterone,XN7MM8XG2M,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213433,1/31/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000AdminCorres.pdf,8/27/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/26/2020,3130,365,1,,,,,,,,,,CCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)CO,3.72449569,,acne vulgaris,Inhibitor,Androgen receptor inhibitor,To treat acne vulgaris,
761149,Enspryng,satralizumab,YB18NF020M,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761149,9/19/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761149Orig1s000MedR.pdf,8/15/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/14/2020,2521,365,1,1,1,1,,,,,,,,,,neuromyelitis optica spectrum disorder,Binding agent,IL-6R-directed mAb,Neuromyelitis optica spectrum disorder,
212154,Viltepso,viltolarsen,SXA7YP6EKX,Neurology,oligonucleotide,oligo,antisense oligo,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212154,6/1/2013,,https://clinicaltrials.gov/ct2/show/NCT02081625,12/12/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/12/2020,2629,244,,1,1,,1,1,,,,,,,,Duchenne muscular dystrophy,,Dystrophin splicing modifier,Duchenne muscular dystrophy,
210730,Olinvyk,oliceridine,MCN858TCP0,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210730,12/22/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf,11/2/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/7/2020,3151,1009,,,1,,,,1,1,,,COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4,4.04193091,,acute pain,Agonist,Opioid receptor agonist,To manage severe acute pain in certain adults,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000OtherActionLtrs.pdf
213535,Evrysdi,risdiplam,76RS4S2ET1,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213535,1/7/2016,,https://clinicaltrials.gov/ct2/show/NCT02633709,9/24/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/7/2020,1674,318,,1,1,,1,,,,,,CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6,1.10231954,,spinal muscular atrophy,,SMN2 splicing modifier,To treat spinal muscular atrophy,
213464,Lampit,nifurtimox,M84I3K7C2O,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213464,11/21/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213464Orig1s000MultidisciplineR.pdf,12/6/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/6/2020,2085,244,,1,,,1,1,,,,,CC1CS(=O)(=O)CCN1\N=C\C2=CC=C(O2)[N+]([O-])=O,-0.3559029,,Chagas disease,,Nitrofuran antiprotozoal,To treat Chagas disease in certain pediatric patients younger than age 18,
761158,Blenrep,belantamab mafodotin,DB1041CXDG,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761158,1/31/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761158Orig1s000MultidisciplineR.pdf,12/5/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/5/2020,2378,244,1,1,,1,1,1,,1,,,,,,multiple myeloma,Inhibitor,"BCMA-directed ADC, with microtubule inhibitor",To treat relapsed or refractory multiple myeloma,
761163,Monjuvi,tafasitamab,QQA9MLH692,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761163,1/29/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf,12/30/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/31/2020,3836,214,1,1,1,1,1,1,,,,,,,,diffuse large B-cell lymphoma,Binding agent,CD19-directed mAb,To treat relapsed or refractory diffuse large B-cell lymphoma,
206966,Xeglyze,abametapir,6UO390AMFB,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206966,12/20/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf,9/14/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/24/2020,4600,1775,1,,,,,,1,,,,CC1=CN=C(C=C1)C2=NC=C(C)C=C2,2.98681964,,head lice,Inhibitor,Metalloproteinase inhibitor,To treat head lice,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000RiskR.pdf
212576,Inqovi,cedazuridine,39IS23Q1EW,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212576,12/18/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212576Orig1s000MultidisciplineR.pdf,12/11/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/7/2020,2393,209,,1,,,1,,,,,,OC[C@H]1O[C@@H](N2CC[C@@H](O)NC2=O)C(F)(F)[C@@H]1O,-1.3698669,,myelodysplastic syndromes,Inhibitor,Cytidine deaminase inhibitor | nucleoside metabolic inhibitor,To treat myelodysplastic syndromes,
212295,Byfavo,remimazolam,7V4A8U16MB,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212295,11/10/2008,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000MedR.pdf,4/5/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/2/2020,4252,454,,,,,,,,1,,,COC(=O)CC[C@@H]1N=C(C2=NC=CC=C2)C3=C(C=CC(Br)=C3)N4C(C)=CN=C14,3.76715619,,procedural sedation,,Benzodiazepine,For procedural sedation,
212950,Rukobia,fostemsavir,97IQ273H4L,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212950,11/8/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212950Orig1s000IntegratedR.pdf,12/4/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/2/2020,5350,211,1,,1,1,1,,,,,,COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N3C=NC(C)=N3)C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5,-0.1817181,,HIV,Inhibitor,Attachment inhibitor,To treat HIV-1,
213687,Dojolvi,triheptanoin,2P6O7CFW5K,Endocrinology,chemical,small molecule,lipid,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213687,7/23/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213687Orig1s000NameR.pdf,7/31/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/30/2020,2534,335,,1,1,,,,,,,,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,7.07855198,,long-chain fatty acid oxidation disorders,,Medium-chain triglyceride,To treat molecularly confirmed long-chain fatty acid oxidation disorders,
213702,Zepzelca,lurbinectedin,2CN60TN6ZS,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213702,10/9/2015,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000AdminCorres.pdf,12/16/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/15/2020,1711,182,,1,,,1,1,,,,,COC1=CC2=C(NC3=C2CCN[C@]34CS[C@H]5[C@H]6[C@@H]7N(C)[C@@H](CC8=CC(C)=C(OC)C(O)=C78)[C@H](O)N6[C@@H](COC4=O)C9=C%10OCOC%10=C(C)C(OC(C)=O)=C59)C=C1,4.61924782,,small-cell lung cancer,,Alkylating drug,To treat metastatic small cell lung cancer,
761142,Uplizna,inebilizumab,74T7185BMM,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761142,2/27/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761142Orig1s000MedR.pdf,6/11/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/11/2020,2296,366,1,1,,1,,,,,,,,,,neuromyelitis optica spectrum disorder,Binding agent,CD19-directed mAb,To treat neuromyelitis optica spectrum disorder,
212123,Tauvid,flortaucipir F 18,T1JP1KYU9O,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212123,10/30/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212123Orig1s000IntegratedR.pdf,9/30/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/28/2020,2402,241,1,,,,1,,,,1,,[18F]C1=NC=C(C=C1)C2=CC=C3C(NC4=C3C=NC=C4)=C2,2.79285576,,"imaging, tau in Alzheimer disease",,Radioactive diagnostic,Diagnostic agent for patients being evaluated for Alzheimer’s disease,
213036,artesunate,artesunate,60W3249T9M,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213036,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf,9/26/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/26/2020,NA,243,,1,1,1,1,,,,,,C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,3.18474771,,severe malaria,,Artemisinin antimalarial,To treat severe malaria,
212155,Cerianna,fluoroestradiol F 18,T32277KB09,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212155,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212155Orig1s000MultidisciplineR.pdf,2/27/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/20/2020,NA,448,,,,,,,,,1,,CC12CCC3C(C1CC(C2O)F)CCC4=C3C=CC(=C4)O,3.52881681,,"imaging, breast cancer",,Radioactive diagnostic,Diagnostic imaging agent for certain patients with breast cancer,
213973,Qinlock,ripretinib,9XW757O13D,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213973,8/11/2015,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000MultidisciplineR.pdf,12/13/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/15/2020,1739,154,,1,1,1,1,,,,,,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC,4.19335804,,gastrointestinal stromal tumor,Inhibitor,KIT and PDGFRA kinase inhibitor,To treat advanced gastrointestinal stromal tumor,
213246,Retevmo,selpercatinib,CEGM9YBNGD,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246,3/2/2017,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf,12/4/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/8/2020,1163,156,,1,,1,1,1,,,,,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,3.11578129,,non-small cell lung cancer and thyroid cancers,Inhibitor,RET kinase inhibitor,To treat metastatic non-small cell lung cancer and thyroid cancers,
213591,Tabrecta,capmatinib,TY34L4F9OZ,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591,11/9/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213591Orig1s000MultidisciplineR.pdf,12/10/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/6/2020,2735,148,,1,,1,1,1,,,,,CNC(=O)C1=C(F)C=C(C=C1)C2=NN3C(CC4=CC5=C(C=C4)N=CC=C5)=CN=C3N=C2,2.91641291,,non-small cell lung cancer,Inhibitor,MET kinase inhibitor,To treat metastatic non-small cell lung cancer,
212489,Ongentys,opicapone,Y5929UIJ5N,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212489,4/30/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000MedR.pdf,4/26/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/24/2020,4012,364,,,,,,,,,,,CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O,3.00941088,,parkinson disease,Inhibitor,COMT inhibitor,To treat patients with Parkinson’s disease experiencing “off” episodes,
761115,Trodelvy,sacituzumab govitecan,M9BYU8XDQ6,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115,6/1/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000MultidisciplineR.pdf,5/18/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/22/2020,2882,705,1,,1,1,1,1,1,1,,,,,,triple-negative breast cancer,Inhibitor,"TROP2-directed ADC, with topoisomerase inhibitor",To treat metastatic triple-negative breast cancer,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000NameR.pdf
213411,Tukysa,tucatinib,234248D0HH,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213411,7/24/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213411Orig1s000MultidisciplineR.pdf,12/20/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/17/2020,4651,119,,1,1,1,1,,,,,,CC1=C(OC2=CC3=NC=NN3C=C2)C=CC(NC4=NC=NC5=CC=C(NC6=NC(C)(C)CO6)C=C45)=C1,5.34746858,,HER2-positive breast cancer,Inhibitor,HER2 kinase inhibitor,To treat advanced unresectable or metastatic HER2-positive breast cancer,
213736,Pemazyre,pemigatinib,Y6BX7BL23K,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736,10/27/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213736Orig1s000MultidisciplineR.pdf,9/30/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/17/2020,1999,200,,1,,1,1,1,,,,,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1.76327624,,cholangiocarcinoma,Inhibitor,FGFR1-3 kinase inhibitor,To treat locally advanced or metastatic cholangiocarcinoma,
213756,Koselugo,selumetinib,6UH91I579U,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213756,3/8/2007,,https://clinicaltrials.gov/ct2/show/NCT00463814,9/13/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/10/2020,4782,210,1,1,,1,1,,,,,,CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC3=C(Cl)C=C(Br)C=C3)=C2F,4.32309223,,neurofibromatosis type 1,Inhibitor,MEK1/2 kinase inhibitor,To treat neurofibromatosis type 1,
209899,Zeposia,ozanimod,Z80293URPV,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209899,1/1/2011,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516232/,3/25/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/25/2020,3371,366,,,,,,,,,,,CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@H](NCCO)C4=CC=C3)C#N,4.05273256,,multiple sclerosis,Modulator,S1P receptor modulator,To treat relapsing forms of multiple sclerosis,
212801,Isturisa,osilodrostat,5YL4IQ1078,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212801,5/30/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000StatR.pdf,3/7/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/6/2020,2472,365,1,1,,,,,,,,,FC1=CC(=CC=C1[C@H]2CCC3=CN=CN23)C#N,2.12438632,,Cushing disease,Inhibitor,Cortisol synthesis inhibitor,To treat Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease,
761113,Sarclisa,isatuximab,R30772KCU0,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761113,12/29/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761113Orig1s000MultidisciplineR.pdf,4/30/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/2/2020,3716,307,,1,,,,,,,,,,,,multiple myeloma,Binding agent,CD38-directed mAb,To treat refractory multiple myeloma,
212728,Nurtec ODT,rimegepant,997WVV895X,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212728,11/18/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212728Orig1s000MedR.pdf,6/27/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/27/2020,3388,245,,,,,1,,,,,,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N3C(=O)NC4=C3C=CC=N4)C5=NC=CC=C15)C6=CC=CC(F)=C6F,2.75178552,,migraine,Antagonist,CGRP receptor antagonist,To treat migraine,
209510,Barhemsys,amisulpride,8110R61I4U,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209510,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf,10/5/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/26/2020,NA,874,,,,,,,1,,,,CCN1CCCC1CNC(=O)C2=C(OC)C=C(N)C(=C2)S(=O)(=O)CC,0.25945742,,nausea and vomiting after surgery,Antagonist,Dopamine D2 receptor antagonist,To help prevent nausea and vomiting after surgery,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000RiskR.pdf
761119,Vyepti,eptinezumab,8202AY8I7H,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119,12/13/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761119Orig1s000MedR.pdf,2/21/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/21/2020,2626,365,,,,,,,,,,,,,,migraine,Binding agent,CGRP-directed mAb,For the preventive treatment of migraine,
211616,Nexletol,bempedoic acid,1EJ6Z6Q368,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211616,9/23/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211616Orig1s000IntegratedR.pdf,2/21/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/21/2020,3803,365,1,,,,,,,,,,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,5.36897513,,atherosclerotic cardiovascular disease,Inhibitor,ACL inhibitor,To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C,
211281,Pizensy,lactitol,L2B0WJF7ZY,Gastroenterology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211281,6/14/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211281Orig1s000MultidisciplineR.pdf,11/21/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/12/2020,2434,448,,,,,,,,,,,OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,-5.519077,,chronic idiopathic constipation,,Osmotic laxative,To treat chronic idiopathic constipation,
211723,Tazverik,tazemetostat,Q40W93WPE1,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,7/23/2015,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211723Orig1s000MultidisciplineR.pdf,5/23/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/23/2020,1645,245,1,1,,,1,1,,,,,CCN(C1CCOCC1)C2=C(C)C(=CC(=C2)C3=CC=C(CN4CCOCC4)C=C3)C(=O)NCC5=C(C)C=C(C)NC5=O,3.37592728,,epithelioid sarcoma,Inhibitor,EZH2 inhibitor,To treat metastatic or locally advanced epithelioid sarcoma,
761143,Tepezza,teprotumumab,Y64GQ0KC0A,Endocrinology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143,4/1/2006,,https://clinicaltrials.gov/ct2/show/NCT00400361,7/8/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/21/2020,5043,197,1,1,1,1,1,,,,,,,,,thyroid eye disease,Binding agent,IGF1R-directed mAb,To treat thyroid eye disease,
212608,Ayvakit,avapritinib,513P80B4YJ,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212608,7/9/2015,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212608Orig1s000MultidisciplineR.pdf,6/14/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/9/2020,1645,209,,1,1,1,1,,,,,,CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N,3.36407598,,gastrointestinal stromal tumor,Inhibitor,"PDGFRA, PDGFRA mutants and KIT kinase inhibitor",To treat unresectable or metastatic gastrointestinal stromal tumor,
211765,Ubrelvy,ubrogepant,AD0O8X2QJR,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211765,2/3/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000MedR.pdf,12/26/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/23/2019,2880,362,,,,,,,,,,,C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC5=C4C=CC=N5)C(=O)N1CC(F)(F)F)C6=CC=CC=C6,2.99899262,first oral CGPR antagonist,migraine,Antagonist,calcitonin gene-related peptide receptor (CGPR),to treat acute treatment of migraine with or without aura in adults,
212028,Dayvigo,lemborexant,0K5743G68X,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212028,7/1/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf,12/27/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/20/2019,3094,358,,,,,,,,,,,CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC3=NC=C(F)C=C3)C4=CC(F)=CC=C4)C(C)=N1,3.43829092,,insomnia,Antagonist,orexin receptors OX1R and OX2R,Insomnia,
209500,Caplyta,lumateperone tosylate,JIE88N006O,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209500,11/15/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf,9/27/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/20/2019,4418,449,,,1,,,,,1,,,CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C5=C2C1=CC=C5,3.54484055,,schizophrenia,Antagonist,5-HT2a and D2 receptors,Schizophrenia,
209569,TissueBlue,brilliant blue G,M1ZRX790SI,Opthamology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209569,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209569Orig1s000MedR.pdf,4/29/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/20/2019,NA,235,,,,,1,,,,1,,CCOC1=CC=C(NC2=CC=C(C=C2)C(=C3C=CC(C=C3C)=[N+](CC)CC4=CC(=CC=C4)S([O-])(=O)=O)C5=C(C)C=C(C=C5)N(CC)CC6=CC(=CC=C6)S([O-])(=O)=O)C=C1,6.77337391,,eye surgery dye,Binding agent,anterior Lens capsule,Dye used in eye surgery,
761139,Enhertu,trastuzumab deruxtecan,5384HK7574,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139,1/27/2016,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761139Orig1s000MultidisciplineR.pdf,8/29/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/20/2019,1423,113,,,1,1,1,1,,1,,,,,,metastatic breast cancer,Inhibitor,topoisomerase,Metastatic breast cancer,
761137,Padcev,enfortumab vedotin,DLE8519RWM,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761137,12/28/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761137Orig1s000MultiDiscliplineR.pdf,7/15/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/18/2019,2546,156,,,,1,1,1,,,,,,,,refractory bladder cancer,Cytotoxic,microtubules,To treat refractory bladder cancer,
211970,Vyondys 53,golodirsen,033072U4MZ,Neurology,oligonucleotide,oligo,antisense oligo,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211970,11/17/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211970Orig1s000MedR.pdf,12/19/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/12/2019,1851,358,1,1,1,,1,1,1,,,,,,,Duchenne muscular dystrophy,Antisense oligonucleotide,dystrophin gene translation,To treat certain patients with Duchenne muscular dystrophy,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211970Orig1s000OtherActionLtrs.pdf
213137,Oxbryta,voxelotor,3ZO554A4Q8,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213137,10/14/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213137Orig1s000AdminCorres.pdf,6/26/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/25/2019,1868,152,1,1,1,1,1,1,,,,,CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O,3.57372971,,sickle cell disease,Modulator,hemoglobin oxygen-affinity,To treat sickle cell disease,
212839,Xcopri,cenobamate,P85X70RZWS,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212839,8/31/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000MedR.pdf,11/21/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/21/2019,5195,365,1,,,,,,,,,,NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2,1.72840451,,partial onset seizures,Blocker,voltage-gated sodium channels,To treat partial onset seizures,
212194,Givlaari,givosiran,ROV204583W,Hematology,oligonucleotide,oligo,siRNA,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212194,9/11/2015,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212194Orig1s000MultidisciplineR.pdf,6/4/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/20/2019,1531,169,1,1,,1,1,,,,,,,,second-ever RNA interference drug,acute hepatic porphyria,Suppressor (RNA interference),aminolevulinic acid synthase 1 (ALAS1),To treat acute hepatic porphyria (a rare blood disorder),
761128,Adakveo,crizanlizumab,L7451S9126,Hematology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761128,2/28/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761128Orig1s000MultidisciplineR.pdf,5/16/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/15/2019,3182,183,1,1,,1,1,,,,,,,,,complication of sickle cell disease,Inhibitor,P-selectin,To treat patients with painful complication of sickle cell disease,
213217,Brukinsa,zanubrutinib,AG9MHG098Z,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213217,8/25/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000MultidisciplineR.pdf,6/27/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/14/2019,1907,140,,1,,1,1,1,,,,,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,3.45685345,,mantle cell lymphoma,Inhibitor,Bruton's tyrosine kinase,To treat certain patients with mantle cell lymphoma which is a form of blood cancer,
209445,Fetroja,cefiderocol,SZ34OMG6E8,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209445,3/22/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209445Orig1s000MultidisciplineR.pdf,12/14/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/14/2019,2428,335,,,1,,1,,,,,,CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]4(CCNC(=O)C3=C(Cl)C(O)=C(O)C=C3)CCCC4)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5)C(O)=O,-2.3738639,,urinary tract infections,Inhibitor,penicillin-binding proteins,To¬†treat patients with complicated urinary tract infections who have limited or no alternative treatment options,
761136,Reblozyl,luspatercept,AQK7UBA1LS,Hematology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761136,7/14/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761136Orig1s000MultidisciplineR.pdf,4/4/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/8/2019,3039,218,1,1,1,,1,,,,,,,,,anemia associated with beta thalassemia,Binding agent,Transforming growth factor-β superfamily proteins,For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions,
212273,Trikafta,elexacaftor,RRN67GMB0V,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212273,12/12/2016,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf,7/19/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/21/2019,1043,94,,1,1,1,1,,,,,,C(C(=CC1)C(=O)NS(=O)(=O)C(C(=N4)C)=CN4C)(=NC=1N(N=C3OCC(C(F)(F)F)(C)C)C=C3)N(C(C2)(C)C)C[C@H]2C,5.1028586,new breakthrough therapy for cystic fibrosis,cystic fibrosis,Binding agent,cystic fibrosis transmembrane conductance regulator (CFTR),To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis,
211280,Reyvow,lasmiditan,760I9WM792,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211280,11/1/2006,,https://clinicaltrials.gov/ct2/show/NCT00384774,10/11/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/11/2019,4727,365,1,,,,,,,,,,CN1CCC(CC1)C(=O)C2=NC(NC(=O)C3=C(F)C=C(F)C=C3F)=CC=C2,3.15434194,,migraine,Agonist,serotonin (5-HT) 1F receptor,For the acute treatment of migraine with or without aura in adults,
200655,Fluorodopa F 18,fluorodopa F-18,2C598205QX,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200655,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/200655Orig1s000MultidisciplineR.pdf,10/22/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/10/2019,NA,2544,,,,,,,1,,1,,N[C@@H](CC1=C([18F])C=C(O)C(O)=C1)C(O)=O,-0.871981,,Parkinsonian syndromes diagnostic,Substrate,amino acid decarboxylase,A diagnostic agent for use in positron emission tomography (PET) to help diagnose adult patients with suspected Parkinsonian syndromes (PS),https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/200655Orig1s000ltr.pdf
210797,Scenesse,afamelanotide,QW68W3J66U,Dermatology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210797,9/1/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000MultidisciplineR.pdf,11/8/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/8/2019,4785,334,1,1,1,,1,,,,,,,,first treatment to help erythropoietic protoporphyria patients increase their light exposure,erythropoietic protoporphyria,Agonist,melanocortin 1 receptor,To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria,
761125,Beovu,brolucizumab,XSZ53G39H5,Opthamology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125,4/20/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761125Orig1s000PharmR.pdf,2/7/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/7/2019,3092,242,1,,,,1,,,,,,,,,age-related macular degeneration,Inhibitor,vascular endothelial growth factor (VEGF),Treatment of wet age-related macular degeneration,
211527,Aklief,trifarotene,0J8RN2W0HK,Dermatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211527,2/3/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf,10/4/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/4/2019,3165,365,1,,,,,,,,,,CC(C)(C)C1=C(C=CC(=C1)C2=C(OCCO)C=CC(=C2)C3=CC=C(C=C3)C(O)=O)N4CCCC4,5.21270745,first retinoid treatment to be approved by the FDA in over 20 years.,acne vulgaris,Agonist,gamma subtype of retinoic acid receptor,For the topical treatment of acne vulgaris in patients 9 years of age and older,
211801,Ibsrela,tenapanor,WYD79216A6,Gastroenterology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211801,10/21/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211801Orig1s000MultidisciplineR.pdf,9/12/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/12/2019,3248,365,,,,,,,,1,,,CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C3=CC(=CC=C3)[C@@H]4CN(C)CC5=C(Cl)C=C(Cl)C=C45)C6=CC(Cl)=CC(Cl)=C6C1,4.93778307,,irritable bowel syndrome with constipation,Inhibitor,sodium/hydrogen exchanger 3 (NHE3),To treat irritable bowel syndrome with constipation in adults.,
22075,Nourianz,istradefylline,2GZ0LIK7T4,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022075,7/1/1996,,https://www.biospace.com/article/releases/kyowa-hakko-kirin-announces-development-policy-for-anti-parkinson-s-disease-drug-kw-6002-istradefylline-/,4/25/2007,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/27/2019,8457,4507,,,,,,,1,,,,CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O,2.3198254,,Parkinson's disease,Antagonist,adenosine A2A receptor,To treat adult patients with Parkinson's disease experiencing off episodes,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000MedR.pdf
210828,Ga 68 DOTATOC,edotreotide gallium Ga-68,Y68179SY2L,Oncology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210828,7/2/2001,,https://link.springer.com/content/pdf/10.1007/s002590100639.pdf,5/23/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/21/2019,6624,455,,1,,,,,,,1,,,,,neuroendocrine tumor diagnostic,Binding agent,somatostatin receptor type 2,For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs),
211672,Xenleta,lefamulin,21904A5386,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000%2C%20211673Orig1s000TOC.cfm,10/17/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000%2C%20211673Orig1s000RiskR.pdf,12/19/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/19/2019,3593,243,1,,1,,1,,,,,,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O,2.8685478,Xenleta received Qualified Infectious Disease Product (QIDP) designation.,community-acquired bacterial pneumonia,Binding agent,23s rRNA of the 50S subunit,To treat adults with community-acquired bacterial pneumonia,
212327,Inrebic,fedratinib,6L1XP550I6,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212327,10/24/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf,1/3/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/16/2019,4314,225,1,1,,,1,,,,,,CC1=C(NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=C1,4.85259986,,myelofibrosis,Inhibitor,Janus Associated Kinase 2 (JAK2) | FMS-like tyrosine kinase 3 (FLT3),To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis,
211675,Rinvoq,upadacitinib,4RA0KN46E0,Rheumatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211675,7/1/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000SumR.pdf,12/18/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/16/2019,2602,241,,,,,1,,,,,,CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F,0.65745147,,rheumatoid arthritis,Inhibitor,Janus kinase (JAK),To treat adults with moderately to severely active rheumatoid arthritis,
212725,Rozlytrek,entrectinib,L5ORF0AN1I,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725,2/27/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000%2C%2520212726Orig1s000MultidisciplineR.pdf,12/18/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/15/2019,1995,240,,1,,1,1,1,,,,,CN1CCN(CC1)C2=CC(NC3CCOCC3)=C(C=C2)C(=O)NC4=NNC5=C4C=C(CC6=CC(F)=CC(F)=C6)C=C5,5.340715,,non-small cell lung cancer,Inhibitor,neurotrophic tyrosine receptor kinases,To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive,
212862,Pretomanid,pretomanid,2XOI31YC4N,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212862,4/28/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000MultidisciplineR.pdf,12/14/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/14/2019,5221,243,,1,1,,1,,,,,,[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC3=CC=C(OC(F)(F)F)C=C3,4.18269535,only the third TB drug approved by the FDA in more than 50 years,tuberculosis,Inhibitor,mycolic acid biosynthesis,For treatment-resistant forms of tuberculosis that affects the lungs,
211150,Wakix,pitolisant,4BC83L4PIY,Psychiatry,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000TOC.cfm,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000SumR.pdf,12/14/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/14/2019,NA,243,1,1,1,,1,,,,,,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,4.16887881,,sleep disorder,Inverse Agonist,histamine-3 (H3) receptors,To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy,
211810,Turalio,pexidartinib,6783M2LV5X,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211810,8/19/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf,12/3/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/2/2019,3635,242,,1,,1,1,,,1,,,FC(F)(F)C1=NC=C(CNC2=CC=C(CC3=CNC4=C3C=C(Cl)C=N4)C=N2)C=C1,4.53274956,,symptomatic tenosynovial giant cell tumor,Inhibitor,colony stimulating factor 1 receptor | KIT proto-oncogene receptor tyrosine kinase | FMS-like tyrosine kinase 3,To treat adult patients with symptomatic tenosynovial giant cell tumor,
212099,Nubeqa,darolutamide,X05U0N2RCO,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212099,7/13/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000ChemR.pdf,2/26/2019,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/30/2019,2573,154,,,1,,1,,,,,,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,2.50738774,,castration-resistant prostate cancer,Inhibitor,androgen receptor,To treat adult patients with non-metastatic castration resistant prostate cancer,
212320,Accrufer,ferric maltol,MA10QYF1Z0,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212320,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212320Orig1s000MultidisciplineR.pdf,9/27/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/25/2019,NA,301,,,,,,,,,,,CC1=C([O-])C(=O)C=CO1,0.56124919,,iron deficiency,Supplement,iron,To treat iron deficiency anemia in adults,
212819,Recarbrio,relebactam,Y1MYA2UHFL,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212819,9/13/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf,11/16/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/16/2019,3228,242,,,1,,1,,,,,,OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC3CCNCC3)C1=O,-2.6679711,,urinary tract infections,Inhibitor,beta lactamases,To treat complicated urinary tract and complicated intra-abdominal infections,
212306,Xpovio,selinexor,31TZ62FO8F,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212306,6/8/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf,8/6/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/3/2019,2581,331,1,1,1,,1,1,,,,,FC(F)(F)C1=CC(=CC(=C1)C2=NN(C=N2)\C=C/C(=O)NNC3=CN=CC=N3)C(F)(F)F,3.12723585,,multiple myeloma,Blocker,exportin 1 (XPO1),To treat adult patients with relapsed or refractory multiple myeloma (RRMM),
210557,Vyleesi,bremelanotide,PV2WI7495P,Endocrinology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557,1/27/2001,,https://www.federalregister.gov/documents/2020/08/20/2020-18240/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyleesi,3/23/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/21/2019,6719,455,1,,,,,,,,,,,,,hypoactive sexual desire disorder,Agonist,melanocortin receptors including MC4R,To treat hypoactive sexual desire disorder in premenopausal women.,
761121,Polivy,polatuzumab vedotin,KG6VO684Z6,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761121,1/7/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761121Orig1s000MedR.pdf,12/19/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/10/2019,3076,173,1,1,,1,1,1,,,,,,,first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma,diffuse large B-cell lymphoma,Cytotoxic,microtubules,To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma,
212526,Piqray,alpelisib,08W5N2C97Q,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526,10/5/2010,,https://clinicaltrials.gov/ct2/show/NCT01219699,12/18/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/24/2019,3153,157,1,,,,1,,,,,,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,2.70947282,first PI3K inhibitor for breast cancer,advanced or metastatic breast cancer,Inhibitor,phosphatidylinositol-3-kinase,To treat breast cancer,
125694,Zolgensma,onasemnogene abeparvovec,MLU3LU3EVV,Neurology,gene therapy,virus,virus,BLA,https://www.fda.gov/vaccines-blood-biologics/zolgensma,8/8/2013,,https://www.fda.gov/media/127961/download,10/1/2018,https://www.fda.gov/media/127961/download,5/24/2019,2115,235,1,1,1,1,1,,,,,,,,innovative gene therapy to treat pediatric patients with spinal muscular atrophy,spinal muscular atrophy,Gene therapy,survival motor neuron 1,To treat pediatric patients less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,
211996,Vyndaqel,tafamidis meglumine,ZU7CF08A1A,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000%2C%20212161Orig1s000TOC.cfm,8/19/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000%2C%20212161Orig1s000PharmR.pdf,11/2/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/3/2019,5005,182,1,1,1,1,1,,,,,,OC(=O)C1=CC=C2N=C(OC2=C1)C3=CC(Cl)=CC(Cl)=C3,4.206292,,transthyretin amyloid cardiomyopathy,Stabiliser,transthyretin,To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000%2C%20212161Orig1s000AdminCorres.pdf
761105,Skyrizi,risankizumab,90ZX3Q3FR7,Dermatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105,2/28/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761105Orig1s000MultidisciplineR.pdf,4/23/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/23/2019,2611,365,,,,,,,,,,,,,,plaque psoriasis,Antibody,p19 subunit of human interleukin 23,To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,
212018,Balversa,erdafitinib,890E37NHMV,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018,3/27/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf,9/18/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/12/2019,2207,206,,,,1,1,1,,,,,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C2=CC3=C(C=C2)N=CC(=N3)C4=CN(C)N=C4,3.64354734,first targeted therapy for metastatic bladder cancer,urothelial carcinoma,Inhibitor,fibroblast growth factor receptors,To treat adult patients with locally advanced or metastatic bladder cancer,
761062,Evenity,romosozumab,3VHF2ZD92J,Osteology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761062,11/1/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761062Orig1s000MultidisciplineR.pdf,7/19/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/9/2019,4542,994,,,,,,,1,1,,,,,,osteoporosis in postmenopausal women,Inhibitor,sclerostin,To treat osteoporosis in postmenopausal women at high risk of fracture,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761062Orig1s000OtherActionLtrs.pdf
209884,Mayzent,siponimod,RR6P8L282I,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209884,9/15/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000MedR.pdf,7/26/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/26/2019,4575,243,,,,,1,,,,,,CCC1=C(CN2CC(C2)C(O)=O)C=CC(=C1)C(\C)=N\OCC3=CC(=C(C=C3)C4CCCCC4)C(F)(F)F,5.09339923,,multiple sclerosis,Modulator,S1P receptors 1 and 5,To treat adults with relapsing forms of multiple sclerosis,
211230,Sunosi,solriamfetol,939U7C91AI,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000TOC.cfm,5/1/2009,,https://link.springer.com/article/10.1007%2Fs40265-019-01123-y,12/20/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/20/2019,3610,455,,1,,,,,,,,,C1=CC=C(C=C1)CC(COC(=O)N)N,0.85850845,,excessive daytime sleepiness,Inhibitor,dopamine and norepinephrine reuptake,To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea,
211371,Zulresso,brexanolone,S39XZ5QV8Y,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211371,7/31/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000MultidisciplineR.pdf,4/19/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/19/2019,1692,334,1,,,1,1,,,1,,,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C,3.94052452,first treatment for post-partum depression,postpartum depression,Modulator,GABAa receptors,To treat postpartum depression (PPD) in adult women,
208711,Egaten,triclabendazole,4784C8E03O,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000TOC.cfm,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf,6/14/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/13/2019,NA,244,1,1,1,,1,,,,,,CSC1=NC2=C(N1)C=C(OC3=C(Cl)C(Cl)=CC=C3)C(Cl)=C2,5.93394035,,fascioliasis,Inhibitor,tubulin function,To treat fascioliasis which is a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver and sometimes referred to as 'liver flukes',
761112,Cablivi,caplacizumab,2R27AB6766,Hematology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761112,7/2/2007,,https://www.ablynx.com/uploads/press-releases/pressreleasealx-0081phase1_en.pdf,6/6/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/6/2019,4237,245,1,1,1,,1,,,,,,,,first therapy for the treatment of adult patients with a rare blood clotting disorder,acquired thrombotic thrombocytopenic purpura,Antibody,von Willebrand factor,To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP),
761085,Jeuveau,botulinum toxin type A,E211KPY694,Dermatology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761085,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761085Orig1s000MultiR.pdf,5/15/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/1/2019,NA,627,,,,,,,1,1,,,,,,improve the look of moderate to severe frown lines,Inhibitor,synaptosome associated protein 25,For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761085Orig1s000MultiR.pdf
761116,Elzonris,tagraxofusp,8ZHS5657EH,Oncology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761116,10/22/2003,,https://www.federalregister.gov/documents/2020/08/31/2020-19085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elzonris,6/21/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/21/2018,5539,183,1,1,,1,1,,,1,,,,,,blastic plasmacytoid dendritic cell neoplasm,Inhibitor,ADP-ribosylation elongation factor 2,To treat blastic plasmacytoid dendritic cell neoplasm (BPDCN),
761108,Ultomiris,ravulizumab,C3VX249T6L,Hematology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761108Orig1s000MultidisciplineR.pdf,6/18/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/21/2018,NA,186,,1,,,1,,,,,,,,,paroxysmal nocturnal hemoglobinuria,Inhibitor,Complement component 5,To treat paroxysmal nocturnal hemoglobinuria (PNH),
761102,Asparlas,calaspargase pegol,T9FVH03HMZ,Oncology,protein,enzyme,PEGlated protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761102,12/19/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761102Orig1s000MultidisciplineR.pdf,12/22/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/20/2018,4019,363,,1,,,,,,,,,,,,acute lymphoblastic leukemia,Enzyme,E. coli L-asparaginase,To treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years,
210166,Motegrity,prucalopride,0A09IUW5TP,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210166,12/1/1994,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf,12/21/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/14/2018,8779,358,,,,,,,,,,,COCCCN1CCC(CC1)NC(=O)C2=C3OCCC3=C(N)C(Cl)=C2,0.74317492,,constipation,Agonist,5-HT4 receptor,To treat chronic idiopathic constipation,
208078,Firdapse,amifampridine,RU4S6E2G0J,Rheumatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1_toc.cfm,1/12/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208078Orig1s000MedR.pdf,3/28/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/28/2018,2877,245,,1,,1,1,,,,,,NC1=CC=NC=C1N,-0.9411379,,Lambert-Eaton myasthenic syndrome,Blocker,KCNA1,To treat Lambert-Eaton myasthenic syndrome (LEMS) in adults,
211349,Xospata,gilteritinib,66D92MGC8M,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1_toc.cfm,6/7/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000RiskR.pdf,3/29/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/28/2018,2000,244,,1,1,,1,,,,,,CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5,2.76451784,,acute myeloid leukemia,Inhibitor,FLT3,To treat patients who have relapsed or refractory acute myeloid leukemia (AML),
210861,Vitrakvi,larotrectinib,PF9462I9HX,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861,2/28/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210861Orig1s000_211710Orig1s000Admincorres.pdf,3/26/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/26/2018,1732,245,1,1,,1,1,1,,,,,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,2.30717962,"Second cancer treatment approval based on genetic makeup, not tumor location",NTRK gene fusion cancers,Inhibitor,Tropomysoin receptor kinases,To treat patients whose cancers have a specific genetic feature (biomarker),
210656,Daurismo,glasdegib,K673DMO5H9,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210656,8/14/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210656Orig1s000MedR.pdf,4/27/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/21/2018,3386,208,,1,,,1,,,1,,,CN1CC[C@H](C[C@@H]1C2=NC3=C(N2)C=CC=C3)NC(=O)NC4=CC=C(C=C4)C#N,2.15431975,,acute myeloid leukemia,Antagonist,Smoothened receptor,To treat newly-diagnosed acute myeloid leukemia (AML) in adult patients,
761107,Gamifant,emapalumab,3S252O2Z4X,Rheumatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761107,9/1/2011,,https://clinicaltrials.gov/ct2/show/NCT01459562,3/20/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/20/2018,2637,245,1,1,,1,1,,,,,,,,,hemophagocytic lymphohistiocytosis,Binding agent,Interferon-gamma,To treat primary hemophagocytic lymphohistiocytosis (HLH),
210910,Aemcolo,rifamycin,DU69T8ZZPA,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210910Orig1_toc.cfm,12/28/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210910Orig1s000MultidisciplineR.pdf,3/16/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/16/2018,3245,245,,,1,,1,,,,,,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O,4.09578923,,travelers' diarrhea,Inhibitor,Bacterial DNA-directed RNA polymerase,To treat travelers' diarrhea,
210598,Yupelri,revefenacin,G2AE2VE07O,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210598,12/12/2007,,https://clinicaltrials.gov/ct2/show/NCT00555022,11/13/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/9/2018,3985,361,,,,,,,,,,,CN(CCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2)C3=CC=CC=C3)C(=O)C4=CC=C(CN5CCC(CC5)C(N)=O)C=C4,3.77466185,,chronic obstructive pulmonary disease,Antagonist,Muscarinic acetylcholine receptor,To treat patients with chronic obstructive pulmonary disease (COPD),
210868,Lorbrena,loratinib,OSP71S83EU,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210868,8/15/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000Admincorres.pdf,12/5/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/2/2018,1905,332,,1,,1,1,1,,,,,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,1.5943347,,non-small cell lung cancer,Inhibitor,ALK and ROS1,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer,
210854,Xofluza,baloxavir marboxil,505CXM6OHG,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210854,4/7/2015,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210854Orig1s000ClinPharmR.pdf,4/24/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/24/2018,1296,183,1,,,,1,,,,,,COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F,3.33716216,first new drug for flu in 20 years,influenza,Inhibitor,Polymerase acidic (PA) protein,For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours.,
211651,Talzenna,talazoparib,9QHX048FRV,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,11/12/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000RiskR.pdf,4/6/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/16/2018,2895,193,,,,,1,,,,,,CN1N=CN=C1[C@@H]2[C@H](NC3=CC(F)=CC4=C3C2=NNC4=O)C5=CC=C(F)C=C5,2.12145924,,metastatic breast cancer,Inhibitor,PARP1 and PARP2,For the treatment of locally advanced or metastatic breast cancer patients with a germline BRCA mutation.,
761092,Revcovi,elapegademase,9R3D3Y0UHS,Hematology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761092,11/3/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761092Orig1s000PharmR.pdf,10/24/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/5/2018,3258,346,,1,1,,1,,,,,,,,,Adenosine Deaminase-Severe Combined Immunodeficiency,Enzyme,Adenosine deaminase,To treat Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID),
211172,Tegsedi,inotersen,0IEO0F56LV,Neurology,oligonucleotide,oligo,antisense oligo,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211172,11/9/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211172Orig1s000MedR.pdf,11/6/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/5/2018,2156,333,1,1,1,,1,,,1,,,,,,transthyretin-mediated amyloidosis,Inhibitor,Transthyretin mRNA,To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,
209816,Nuzyra,omadacycline,090IP5RV8F,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000%2C209817Orig1s000TOC.cfm,6/1/2005,,https://link.springer.com/article/10.1007%2Fs40265-018-1015-2,2/2/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/2/2018,4871,242,,,1,,1,,,,,,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C,-1.3205581,,pneumonia and acute skin infections,Inhibitor,30S ribosomal subunit,To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections,
209521,Seysara,sarecycline,94O110CX2E,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209521,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf,10/20/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/1/2018,NA,346,,,,,,,,,,,CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O,-2.2267456,,severe acne,Inhibitor,Ribosomal protein,To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older,
761097,Libtayo,cemiplimab,6QVL057INT,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097,12/22/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761097Orig1s000OtherR.pdf,2/28/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/28/2018,1376,212,,,,1,1,,,,,,,,,cutaneous squamous cell carcinoma,Inhibitor,Programmed cell death protein 1,To treat cutaneous squamous cell carcinoma (CSCC),
761063,Emgality,galcanezumab,55KHL3P693,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761063,3/4/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761063Orig1s000MedR.pdf,9/27/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/27/2018,2764,365,,,,,,,,,,,,,,migraine,Antagonist,Calcitonin-gene-related peptide (CGRP),For the preventive treatment of migraine in adults,
211288,Vizimpro,dacomitinib,5092U85G58,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288,7/14/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf,1/31/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/27/2018,4823,239,,1,,,1,,,,,,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1,4.77996663,,non-small-cell lung cancer,Inhibitor,EGFR,To treat metastatic non-small-cell lung cancer,
211155,Copiktra,duvelisib,610V23S0JI,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000TOC.cfm,8/18/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf,2/5/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/24/2018,2594,231,,1,1,,1,1,,1,,,C[C@H](NC1=C2N=CNC2=NC=N1)C3=CC4=C(C(Cl)=CC=C4)C(=O)N3C5=CC=CC=C5,3.64245329,,"chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma",Inhibitor,PI3K-γ and PI3K-δ,"To treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma",
761089,Ajovy,fremanezumab,PF8K38CG54,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761089,10/27/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761089Orig1s000MedR.pdf,10/16/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/14/2018,3244,333,,,,,1,,,,,,,,,migraine,Antagonist,Calcitonin-gene-related peptide (CGRP),For the preventive treatment of migraine in adults,
761104,Lumoxiti,moxetumomab pasudotox,2NDX4B6N8F,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761104,11/17/2006,,https://www.federalregister.gov/documents/2020/09/01/2020-19214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumoxiti,1/29/2018,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/13/2018,4318,227,1,1,1,,1,,,1,,,,,,hairy cell leukemia,Binding agent,B-cell receptor CD22,To treat hairy cell leukemia,
210806,Pifeltro,doravirine,913P6LK81M,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000%2C210807Orig1s000TOC.cfm,8/11/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210806Orig1s000%2C%20210807Orig1s000MultidisciplineR.pdf,10/23/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/30/2018,2576,311,,,,,,,,,,,CN1C(=O)NN=C1CN2C=CC(=C(OC3=CC(Cl)=CC(=C3)C#N)C2=O)C(F)(F)F,1.93712927,,HIV-1,Inhibitor,HIV-1 reverse transcriptase,To treat HIV-1 infection in adult patients,
211109,Xerava,eravacycline,07896928ZC,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211109,8/20/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf,12/28/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/27/2018,3294,242,,,1,,1,,,,,,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(NC(=O)CN5CCCC5)C=C4F,-2.4500969,,bacterial infections,Inhibitor,Protein 30S ribosomal subunit,To treat complicated intra-abdominal infections in patients 18 years of age and older,
761090,Takhzyro,lanadelumab,2372V1TKXK,Endocrinology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761090,7/25/2013,,https://www.federalregister.gov/documents/2020/09/14/2020-20104/determination-of-regulatory-review-period-for-purposes-of-patent-extension-takhzyro,12/26/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/23/2018,1855,240,,1,1,1,1,,,,,,,,,hereditary angioedema,Inhibitor,Plasma kallikrein (KLKB1),To treat types I and II hereditary angioedema,
761094,Oxervate,cenegermin,B6E7K36KT8,Opthamology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761094,8/1/2014,,https://www.federalregister.gov/documents/2020/08/20/2020-18239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxervate,12/22/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/22/2018,1482,243,1,1,1,1,1,,,,,,,,,neurotrophic keratitis,Agonist,TrkA and 75NTR,To treat neurotrophic keratitis,
206709,Diacomit,stiripentol,R02XOT8V8I,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000%2C207223Orig1s000TOC.cfm,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000%2C207223Orig1s000MedR.pdf,12/20/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/20/2018,NA,243,,1,,,1,,,,,,CC(C)(C)C(O)C=CC1=CC2=C(OCO2)C=C1,3.05766121,,Dravet syndrome,Agonist,GABA-A receptor,To treat seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam,
210922,Onpattro,patisiran,50FKX8CB2Y,Neurology,oligonucleotide,oligo,siRNA,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210922,3/1/2012,,https://clinicaltrials.gov/ct2/show/NCT01559077,12/11/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/10/2018,2353,242,1,1,1,1,1,,,,,,,,first siRNA drug to be approved,transthyretin-mediated amyloidosis,Suppressor (RNA interference),Transthyretin mRNA,To treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients,
209627,Annovera,segesterone acetate,9AMX4Q13CC,Gynecology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209627,7/13/1997,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209627Orig1s000MultidisciplineR.pdf,8/17/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/10/2018,7698,358,,,,,,,,,,,CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,3.62556113,,birth control,Agonist,Progesterone receptor,New vaginal ring used to prevent pregnancy for an entire year,
208623,Galafold,migalastat,C4XNY919FW,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208623,7/25/2004,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf,12/13/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/10/2018,5129,240,1,1,1,,1,1,,,,,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,-2.8976698,,Fabry disease,Stabiliser,Alpha-galactosidase A,To treat treat adults with Fabry disease.,
761051,Poteligeo,mogamulizumab,YI437801BE,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761051,12/4/2008,,https://www.federalregister.gov/documents/2020/08/31/2020-19036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-poteligeo,10/4/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/8/2018,3534,308,1,1,,1,1,,,,,,,,,non-Hodgkin lymphoma,Antagonist,CXCR4,To treat two rare types of non-Hodgkin lymphoma,
210923,Mulpleta,lusutrombopag,6LL5JFU42F,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210923,1/8/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000MultidisciplineR.pdf,12/26/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/31/2018,3491,217,,,1,,1,,,,,,CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C2=CSC(NC(=O)C3=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C3)=N2,8.66463809,,thrombocytopenia,Agonist,Thrombopoietin receptor,To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure,
210589,Omegaven,fish oil triglycerides,XGF7L72M0F,Hepatology,chemical,lipid,lipid,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210589,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210589Orig1s000MultidisciplineR.pdf,12/1/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/27/2018,NA,238,,1,1,,1,,,,,,,,,nutrition-associated cholestasis,Agonist,Diacylglycerol O-acyltransferase 2|Free fatty acid receptor 4,As a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis,
210450,Orilissa,elagolix sodium,5948VUI423,Gynecology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210450,7/21/2003,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf,8/23/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/23/2018,5481,334,1,,,,1,,,,,,COC1=CC=CC(=C1F)C2=C(C)N(CC3=C(F)C=CC=C3C(F)(F)F)C(=O)N(C[C@H](NCCCC([O-])=O)C4=CC=CC=C4)C2=O,3.81497636,,pain associated with endometriosis,Antagonist,Gonadotropin-releasing hormone receptor (GnRH),For the management of moderate to severe pain associated with endometriosis,
211192,Tibsovo,ivosidenib,Q2PCN8MAM6,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,12/20/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf,12/21/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/20/2018,1673,211,1,1,1,,1,,,,,,FC1=CC(=CN=C1)N([C@H](C(=O)NC2CC(F)(F)C2)C3=C(Cl)C=CC=C3)C(=O)[C@@H]4CCC(=O)N4C5=NC=CC(=C5)C#N,3.11428215,first drug in class - IDH1 inhibitors,acute myeloid leukemia,Inhibitor,Isocitrate dehydrogenase-1,To treat patients with relapsed or refractory acute myeloid leukemia,
210795,Krintafel,tafenoquine,262P8GS9L9,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210795,5/1/1998,,https://doi.org/10.4269/ajtmh.1998.58.645,11/22/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/20/2018,7385,240,,1,,1,1,,,,,,COC1=NC2=C(C(C)=C1)C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C2NC(C)CCCN,4.97863473,first single-dose medicine to prevent the relapse of P. vivax malaria,Plasmodium vivax malaria,Inhibitor,Heme polymerase,For the radical cure (prevention of relapse) of Plasmodium vivax malaria,
208627,TPOXX,tecovirimat,F925RR824R,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208627,11/9/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208627Orig1s000MicroR.pdf,12/8/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/13/2018,4629,217,1,1,1,,1,,,,,1,FC(F)(F)C1=CC=C(C=C1)C(=O)NN2C(=O)[C@H]3[C@H]([C@H]4C=C[C@@H]3[C@@H]5C[C@H]45)C2=O,2.0274543,Animal Rule approval for smallpox,smallpox,Inhibitor,Viral p37,To treat smallpox,
210498,Mektovi,binimetinib,181R97MR71,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498,8/1/2009,,https://clinicaltrials.gov/ct2/show/NCT00959127,6/30/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/27/2018,3252,362,,1,,,,,,,,,CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC3=C(F)C=C(Br)C=C3)=C2F,3.8493662,,melanoma,Inhibitor,MEK 1/2,To treat unresectable or metastatic melanoma,
210496,Braftovi,encorafenib,8L7891MRB6,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,5/12/2011,,https://downloads.regulations.gov/FDA-2019-E-3064-0003/attachment_1.pdf,6/30/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/27/2018,2603,362,,1,,,,,,,,,COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C2=CN(N=C2C3=C(F)C(NS(C)(=O)=O)=CC(Cl)=C3)C(C)C,2.56455251,,melanoma,Inhibitor,BRAF,To treat unresectable or metastatic melanoma,
210303,Zemdri,plazomicin,LYO9XZ250J,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210303,11/30/2001,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210303Orig1s000AdminCorres.pdf,10/25/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/25/2018,6051,243,,,,,1,,,1,,,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O,-5.9049805,,urinary tract infection,Inhibitor,Bacterial ribosome,To treat adults with complicated urinary tract infections,
210365,Epidiolex,cannabidiol,19GBJ60SN5,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210365,3/31/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000MedR.pdf,10/27/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/25/2018,1547,241,,1,1,,1,,,,,,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,6.29260353,,Lennox-Gastaut syndrome or Dravet syndrome,,,"To treat rare, severe forms of epilepsy",
210867,Moxidectin,moxidectin,NGU5H31YO9,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210867,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000MedR.pdf,10/13/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/13/2018,NA,243,,1,,,1,,,,,,CO\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C,5.67884891,neglected disease treatment developed largely outside US,onchocerciasis,,,To treat onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older,
207924,Olumiant,baricitinib,ISP4442I3Y,Rheumatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207924,6/5/2008,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000MedR.pdf,1/15/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/31/2018,3647,867,,,,,,,1,1,,,CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4,-0.1426536,,rheumatoid arthritis,Inhibitor,Janus kinases JAK1 and JAK2,To treat moderately to severely active rheumatoid arthritis,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/207924Orig1s000ltr.pdf
761079,Palynziq,pegvaliase,N6UAH27EUV,Endocrinology,protein,enzyme,PEGlated protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761079,12/27/2007,,https://www.federalregister.gov/documents/2019/12/06/2019-26327/determination-of-regulatory-review-period-for-purposes-of-patent-extension-palynziq,6/30/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/24/2018,3801,328,1,1,1,,1,,,,,,,,,phenylketonuria,Enzyme,Phenylalanine ammonia-lyase,To treat adults with a rare and serious genetic disease known as phenylketonuria (PKU),
210238,Doptelet,avatrombopag,3H8GSZ4SQL,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210238,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf,9/21/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/21/2018,NA,242,,,,,1,,,,,,OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6,5.07782266,,thrombocytopenia,Agonist,Thrombopoietin (TPO) receptor,To treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure,
207078,Lokelma,sodium zirconium cyclosilicate,D652ZWF066,Endocrinology,polymer,polymer,polymer,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207078,12/1/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207078Orig1s000MedR.pdf,5/26/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/18/2018,2725,1088,,,,,,,1,,,,,,,hyperkalemia,Chelator,Potassium,To treat hyperkalemia,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207078Orig1s000RiskR.pdf
761077,Aimovig,erenumab,I5I8VB78VT,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761077,10/16/2012,,https://www.federalregister.gov/documents/2019/12/03/2019-26081/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aimovig,5/17/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/17/2018,2039,365,1,,,,,,,,,,,,first calcitonin gene-related peptide (CGRP) receptor inhibitor to win approval,migraine,Antibody,Calcitonin gene-related peptide (CGRP) receptor,For the preventive treatment for migraine,
209229,Lucemyra,lofexidine hydrochloride,V47G1SDI1B,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209229,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf,9/26/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/16/2018,NA,232,,,1,,1,,,,,,CC(OC1=C(Cl)C=CC=C1Cl)C2=NCCN2,2.61528933,,opioid withdrawal symptoms,Agonist,"α-2A, 2B, and 2C adrenergic receptor",For the non-opioid treatment for management of opioid withdrawal symptoms in adults,
125586,Andexxa,andexanet alfa,BI009E452R,Hematology,protein,enzyme,enzyme,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/andexxa-coagulation-factor-xa-recombinant-inactivated-zhzo,5/25/2012,,https://www.federalregister.gov/documents/2019/12/05/2019-26251/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andexxa,12/17/2015,https://www.fda.gov/media/113954/download,5/3/2018,2169,868,1,1,,1,1,1,1,,,,,,,reversal of anticoagulation,Enzyme,Factor Xa,"For patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.",https://www.fda.gov/media/113954/download
210493,Akynzeo,fosnetupitant,T672P80L2S,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210493Orig1s000ApprovTOC.cfm,9/10/2009,,https://www.federalregister.gov/documents/2018/02/12/2018-02756/determination-of-regulatory-review-period-for-purposes-of-patent-extension-akynzeo,4/20/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/19/2018,3143,364,,,,,,,,,,,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C2=C(C=C(N=C2)N3CC[N+](C)(COP(O)([O-])=O)CC3)C4=C(C)C=CC=C4,2.09709859,,chemotherapy-induced nausea and vomiting,Antagonist,P/neurokinin-1 (NK-1) receptor,To prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy,
761068,Crysvita,burosumab,G9WJT6RD29,Endocrinology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761068,10/3/2008,,https://www.federalregister.gov/documents/2019/11/29/2019-25821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crysvita,8/17/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/17/2018,3483,243,1,1,1,1,1,,,,,,,,first drug approved to treat x-linked hypophosphatemia,X-linked hypophosphatemia,Antibody,Fibroblast growth factor 23,"To treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets",
209299,Tavalisse,fostamatinib,SQ8A3S5101,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209299,6/30/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209299Orig1s000MultidisciplineR.pdf,4/17/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/17/2018,4309,365,1,1,,,,,,,,,COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=N2)=CC(OC)=C1OC,1.78436135,,thrombocytopenia,Inhibitor,Spleen tyrosine (SYK) kinase,To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP),
761067,Ilumya,tildrakizumab,DEW6X41BEK,Rheumatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761067,10/8/2008,,https://www.federalregister.gov/documents/2020/03/03/2020-04362/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilumya,3/23/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/20/2018,3450,362,,,,,,,,,,,,,,psoriasis,Antibody,Interleukin-23,To treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy,
761065,Trogarzo,ibalizumab,LT369U66CE,Antiviral,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761065,4/16/2001,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761065Orig1s000MedR.pdf,5/3/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/6/2018,6168,307,1,1,1,1,1,,,,,,,,,HIV-1,Antibody,Cluster of differentiation 4 (CD4),To treat HIV patients who have limited treatment options,
210951,Erleada,apalutamide,4T36H88UA7,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210951,2/17/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210951Orig1s000ChemR.pdf,10/10/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/14/2018,3284,127,,,1,,1,,,,,,CNC(=O)C1=C(F)C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C#N)C(=C4)C(F)(F)F,3.47728435,approval is the first to use the endpoint of metastasis-free survival,prostate cancer,Neutral antagonist,Androgen receptor,To treat a certain type of prostate cancer using novel clinical trial endpoint,
210491,Symdeko,tezacaftor,8RW88Y506K,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210491,4/15/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210491Orig1s000MedR.pdf,6/28/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/12/2018,2860,229,,1,1,1,1,,,,,,CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO,3.8911405,,cystic fibrosis,Corrector,Cystic fibrosis transmembrane conductance regulator,To treat cystic fibrosis in patients age 12 years and older,
210251,Biktarvy,bictegravir,8GB79LOJ07,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210251,4/28/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000MultidisciplineR.pdf,6/12/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/7/2018,1381,240,,,,,1,,,1,,,OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC5=C(F)C=C(F)C=C5F)C1=O,1.37599118,,HIV-1,Inhibitor,HIV integrase,To treat infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen,
208700,Lutathera,lutetium oxodotreotide LU-177,AE221IM3BB,Oncology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700,1/1/2000,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000MultidisciplineR.pdf,4/28/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/26/2018,6600,638,1,1,1,,1,,1,,,,,,first time a radiopharmaceutical has been approved for the treatment of GEP-NETs,gastroenteropancreatic neuroendocrine tumors,Antagonist,Serotonin receptor,To treat a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000OtherActionLtrs.pdf
209360,Giapreza,angiotensin II,M089EFU921,Endocrinology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209360,6/28/2013,,https://www.federalregister.gov/documents/2019/09/05/2019-19110/determination-of-regulatory-review-period-for-purposes-of-patent-extension-giapreza,6/29/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/21/2017,1637,175,1,,,,1,,,,,,,,New treatment option for critically ill hypotensive patients,septic shock,Agonist,angiotensin II receptor type 1,Increase blood pressure in adults with septic or other distributive shock,
205598,Macrilen,macimorelin,8680B21W73,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205598,2/7/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000MedR.pdf,11/5/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/20/2017,3969,1506,1,1,,,,,1,,,,CC(C)(N)C(=O)N[C@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC3=CNC4=C3C=CC=C4)NC=O,1.65514346,,growth hormone deficiency diagnostic,Agonist,growth hormone secretagogue receptor,Diagnosis of patients with adult growth hormone deficiency (AGHD),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000MedR.pdf
209803,Steglatro,ertugliflozin,6C282481IP,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803%2C209805%2C209806Orig1s000TOC.cfm,10/16/2009,,https://clinicaltrials.gov/ct2/show/NCT00989079,12/19/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/19/2017,2986,365,,,,,,,,,,,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)C=C1,2.34254193,,type 2 diabetes mellitus,Antagonist,Sodium/glucose cotransporter 2,Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate.,
125610,Luxturna,voretigene neparvovec,2SPI046IKD,Opthamology,gene therapy,virus,virus,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna,7/18/2007,,https://www.federalregister.gov/documents/2019/12/05/2019-26252/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luxturna,5/16/2017,https://www.fda.gov/media/110141/download,12/19/2017,3807,217,1,1,,1,1,,,,,,,,First rare-disease gene therapy approved,RPE65 retinal dystrophy,Gene therapy,RPE65,Adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.,
208254,Rhopressa,netarsudil,W6I5QDT7QI,Opthamology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208254,3/7/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208254Orig1s000PharmR.pdf,2/28/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/18/2017,2112,293,1,,,,,,,,,,CC1=CC(C)=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4,4.71942322,,ocular hypertension,Inhibitor,Rho kinase and Norepinephrine transporter,Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.,
208945,Xepi,ozenoxacin,V0LH498RFO,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208945,3/26/2010,,https://www.federalregister.gov/documents/2020/07/13/2020-15013/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xepi,6/23/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/11/2017,2817,536,,,,,,,1,,,,CNC1=C(C)C=C(C=N1)C2=C(C)C3=C(C=C2)C(=O)C(=CN3C4CC4)C(O)=O,2.70150177,,impetigo,Inhibitor,Bacterial DNA gyrase,To treat impetigo,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208945Orig1s000SumR.pdf
209637,Ozempic,semaglutide,53AXN4NNHX,Endocrinology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637,10/19/2008,,https://www.federalregister.gov/documents/2019/11/29/2019-25850/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ozempic,12/5/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/5/2017,3334,365,,,,,,,,1,,,,,,type 2 diabetes mellitus,Agonist,Glucagon-like peptide-1 receptor,To improve glycemic control in adults with type 2 diabetes mellitus,
761083,Hemlibra,emicizumab,7NL2E3F6K3,Hematology,protein,antibody,bispecific antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761083,8/1/2012,,https://clinicaltrials.gov/ProvidedDocs/60/NCT03020160/Prot_000.pdf,6/23/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/16/2017,1933,146,1,1,,1,1,,,1,,,,,First-in-class therapy that works by bridging coagulation factor IX and to factor X,hemophilia A,Antagonist,Factor VIII (FVIII) inhibitor antibodies,To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors,
761047,Mepsevii,vestronidase alfa,7XZ4062R17,Endocrinology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761047,10/9/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761047Orig1s000MedR.pdf,3/16/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/15/2017,1498,244,1,1,1,,1,,,1,,,,,First FDA-approved treatment for mucopolysaccharidosis type VII,mucopolysaccharidosis type VII,Enzyme replacement,Vestronidase alfa,To treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII)- also known as Sly syndrome.,
761070,Fasenra,benralizumab,71492GE1FX,Respiratory,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761070,7/30/2006,,https://www.federalregister.gov/documents/2020/03/04/2020-04363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fasenra,11/16/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/14/2017,4125,363,,,,,,,,,,,,,,severe asthma,Antagonist,Interleukin-5 receptor,For add-on maintenance treatment of patients with severe asthma aged 12 years and older- and with an eosinophilic phenotype,
209939,Prevymis,letermovir,1H09Y5WO1F,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000%2C209940Orig1s000TOC.cfm,3/20/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000%2C209940Orig1s000MedR.pdf,3/8/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/8/2017,3155,245,1,1,1,1,1,,,,,,COC1=CC(=CC=C1)N2CCN(CC2)C3=NC4=C(F)C=CC=C4[C@H](CC(O)=O)N3C5=C(OC)C=CC(=C5)C(F)(F)F,5.18499597,First new medicine for CMV infection approved in 15 years,cytomegalovirus,Inhibitor,Cytomegalovirus,To prevent infection after bone marrow transplant,
207795,Vyzulta,latanoprostene bunod,I6393O0922,Opthamology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207795,2/20/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207795Orig1s000MedR.pdf,7/21/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/2/2017,3908,835,,,,,,,1,,,,O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC2=CC=CC=C2,3.78953089,,ocular hypertension,Agonist,Nitrous oxide-donating prostaglandin,To treat intraocular pressure in patients with open-angle glaucoma or ocular hypertension.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207795Orig1s000Admincorres.pdf
210259,Calquence,acalabrutinib,I42748ELQW,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210259,11/27/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210259Orig1s000MultidisciplineR.pdf,6/13/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/31/2017,1434,140,,1,,1,1,1,,,,,CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=NC=CC=C5,2.43595147,2nd generation Bruton's tyrosine kinase inhibitor,mantle cell lymphoma,Inhibitor,Tyrosine-protein kinase BTK,To treat adults with mantle cell lymphoma,
125643,Yescarta,axicabtagene ciloleucel,U2I8T43Y7R,Oncology,gene therapy,virus,T cell,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel,12/3/2008,,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,3/31/2017,https://www.fda.gov/media/108788/download,10/18/2017,3241,201,,1,,1,1,,,,,,,,Second gene therapy ever approved,B-cell lymphoma,Cytotoxic,anti-CD19 chimeric antigen receptor T-cells,To treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment,
208716,Verzenio,abemaciclib,60UAB198HK,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,10/16/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208716Orig1s000MultidisciplineR.pdf,5/5/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/28/2017,2904,146,,,1,1,1,,,,,,CCN1CCN(CC2=CN=C(NC3=NC(C4=CC(F)=C5N=C(C)N(C(C)C)C5=C4)=C(F)C=N3)C=C2)CC1,4.43216313,,breast cancer,Inhibitor,Cyclin-dependent kinase 4 and 6,To treat certain advanced or metastatic breast cancers,
209363,Solosec,secnidazole,R3459K699K,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209363,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209363Orig1s000MedR.pdf,1/17/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/15/2017,NA,241,,,1,,1,,,,,,CC(O)CN1C(C)=NC=C1[N+]([O-])=O,-0.0310795,,bacterial vaginosis,Inhibitor,Trichomonas vaginalis,To treat bacterial vaginosis,
209936,Aliqopa,copanlisib,WI6V529FZ9,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209936Orig1_toc.cfm,11/19/2009,,https://clinicaltrials.gov/ct2/show/NCT00962611,3/16/2017,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/14/2017,2856,182,,1,1,,1,1,,,,,COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N4CCN=C4C2=CC=C1OCCCN5CCOCC5,0.29533753,,follicular lymphoma,Inhibitor,PI3-kinase,To treat adults with relapsed follicular lymphoma,
125646,Kymriah,tisagenlecleucel,Q6C9WHR03O,Oncology,gene therapy,virus,T cell,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel,8/17/2011,,https://clinicaltrials.gov/ct2/show/NCT01626495,2/2/2017,https://www.fda.gov/media/107962/download,8/30/2017,2205,209,1,1,,1,1,,,,,,,,First gene therapy ever approved,acute lymphoblastic leukemia,Cytotoxic,anti-CD19 chimeric antigen receptor T-cells,To treat certain pediatric and young adult patients with a form of acute lymphoblastic leukemia,
209776,Vabomere,vaborbactam,1C75676F8V,Opthamology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209776,12/3/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209776Orig1s000ClinPharmR.pdf,12/29/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/29/2017,1730,243,,,1,,1,,,,,,OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2,1.8551,,urinary tract infections,Inhibitor,beta-lactamase activity,To treat adults with complicated urinary tract infections,
209570,benznidazole,benznidazole,YC42NRJ1ZD,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209570,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000MedR.pdf,12/29/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/29/2017,NA,243,,1,,,1,1,,,,,[O-][N+](=O)C1=NC=CN1CC(=O)NCC2=CC=CC=C2,1.33437434,First US approval to treat Chagas Disease,Chagas disease,Substrate,Pyruvate:ferredoxin oxidoreductase,To treat children ages 2 to 12 years old with Chagas disease,
761040,Besponsa,inotuzumab ozogamicin,P93RUU11P7,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040,2/16/2003,,https://www.federalregister.gov/documents/2018/10/22/2018-22958/determination-of-regulatory-review-period-for-purposes-of-patent-extension-besponsa,12/20/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/17/2017,5296,240,1,1,,1,1,,,1,,,,,,acute lymphoblastic leukemia,,,To treat adults with relapsed or refractory acute lymphoblastic leukemia,
209394,Mavyret,glecaprevir|pibrentasvir,K6BUU8J72P|2WU922TK3L,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394_toc.cfm,11/14/2012,,https://www.federalregister.gov/documents/2020/01/22/2020-00936/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mavyret,12/14/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/3/2017,1723,232,,,1,1,1,,,1,,,CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C,4.06672328,,hepatitis C,,,To treat adults with chronic hepatitis C virus,
209606,Idhifa,enasidenib,3T1SS4E7AG,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,7/18/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000RiskR.pdf,12/30/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/1/2017,1475,214,1,1,1,,1,,,1,,,CC(C)(O)CNC1=NC(NC2=CC(=NC=C2)C(F)(F)F)=NC(=N1)C3=NC(=CC=C3)C(F)(F)F,4.61270481,,acute myeloid leukemia,Inhibitor,"Isocitrate dehydrogenase [NADP], mitochondrial",To treat relapsed or refractory acute myeloid leukemia,
209195,Vosevi,voxilaprevir,0570F37359,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209195_toc.cfm,3/13/2014,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209195Orig1s000ClinPharmR.pdf,12/8/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/18/2017,1223,222,,,,,1,,,,,,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C,5.00436937,,hepatitis C,,,To treat adults with chronic hepatitis C virus,
208051,Nerlynx,neratinib,9RM7XY23ZS,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051,7/31/2003,,https://www.federalregister.gov/documents/2019/08/30/2019-18816/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nerlynx,7/19/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/17/2017,5100,363,,,,,,,,,,,CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(OCC4=NC=CC=C4)C=C3,4.46561897,,breast cancer,Inhibitor,Epidermal growth factor receptor erbB1 and erbB-2,To reduce the risk of breast cancer returning,
761061,Tremfya,guselkumab,089658A12D,Dermatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761061,5/30/2009,,https://www.federalregister.gov/documents/2018/10/17/2018-22571/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tremfya,11/16/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/13/2017,2966,239,,,,,1,,,,,,,,,psoriasis,,,For the treatment of adult patients with moderate-to-severe plaque psoriasis,
208383,Bevyxxa,betrixaban,74RWP7W0J9,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208383,11/11/2005,,https://www.federalregister.gov/documents/2019/08/30/2019-18788/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bevyxxa,10/24/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/23/2017,4242,242,,,1,,1,,,1,,,COC1=CC(C(=O)NC2=NC=C(Cl)C=C2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1,3.18138188,,venous thromboembolism,Inhibitor,Coagulation factor X,For the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness,
208610,Baxdela,delafloxacin,6315412YVF,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208610,7/22/2001,,https://www.federalregister.gov/documents/2019/06/11/2019-12299/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baxdela-tablets-nda,10/19/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/19/2017,5811,243,,,1,,1,,,1,,,NC1=C(F)C=C(F)C(=N1)N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23,2.57355652,,bacterial skin infection,Inhibitor,Antibacterial antibiotic,To treat patients with acute bacterial skin infections,
761037,Kevzara,sarilumab,NU90V55F8I,Rheumatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761037,11/15/2007,,https://www.federalregister.gov/documents/2018/11/30/2018-26033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kevzara,10/30/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/22/2017,3476,570,,,,,,,1,1,,,,,,rheumatoid arthritis,,,To treat adult rheumatoid arthritis,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761037orig1s000medr.pdf
209176,Radicava,edaravone,S798V6YJRP,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209176,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf,6/16/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/5/2017,NA,323,1,1,,,,,,,,,CC1=NN(C(=O)C1)C2=CC=CC=C2,1.46116387,US approval of Japanese antioxidant therapy for ALS,amyotrophic lateral sclerosis (ALS),,,To treat patients with amyotrophic lateral sclerosis (ALS),
761069,Imfinzi,durvalumab,28X28X9OKV,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,7/13/2012,,https://www.federalregister.gov/documents/2018/10/19/2018-22806/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imfinzi,10/13/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/1/2017,1753,200,,,,1,1,1,,,,,,,,urothelial carcinoma,,,To treat patients with locally advanced or metastatic urothelial carcinoma,
207997,Rydapt,midostaurin,ID912S5VON,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,11/19/1998,,https://www.federalregister.gov/documents/2018/12/28/2018-28216/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rydapt,8/29/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/28/2017,6735,242,1,1,1,1,1,,,,,,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5CNC8=O)N(C)C(=O)C9=CC=CC=C9,5.44468696,,acute myeloid leukemia,Inhibitor,Receptor-type tyrosine-protein kinase FLT3,To treat acute myeloid leukemia,
208772,Alunbrig,brigatinib,HYW8DB273J,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208772,7/26/2011,,https://www.federalregister.gov/documents/2019/06/11/2019-12320/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alunbrig,8/29/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/28/2017,2103,242,,1,,1,1,1,,,,,COC1=C(NC2=NC(NC3=C(C=CC=C3)P(C)(C)=O)=C(Cl)C=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5,3.659,,non-small cell lung cancer,Inhibitor,ALK tyrosine kinase receptor,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,
208743,Tymlos,abaloparatide,AVK0I6HY2U,Osteology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208743,1/8/2006,,https://www.federalregister.gov/documents/2018/10/22/2018-22956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tymlos,3/30/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/28/2017,4128,394,,,,,,,,1,,,,,,osteoporosis,,,To treat osteoporosis in postmenopausal women at high risk of fracture or those who have failed other therapies,
761052,Brineura,cerliponase alfa,X8R2D92QP1,Neurology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761052,9/1/2013,,https://clinicaltrials.gov/ct2/show/NCT01907087,5/27/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/27/2017,1334,335,1,1,,1,1,,,,,,,,First enzyme replacement therapy for a form of Batten disease,Batten disease,,,To treat a specific form of Batten disease,
209241,Ingrezza,valbenazine,54K37P50KH,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209241,12/21/2009,,https://www.biospace.com/article/releases/neurocrine-biosciences-inc-advances-vmat2-inhibitor-program-/,8/11/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/11/2017,2668,243,,,1,1,1,,,,,,COC1=CC2=C(C=C1OC)[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CC2,3.68717237,,tardive dyskinesia,,,To treat adults with tardive dyskinesia,
208082,Austedo,deutetrabenazine,P341G6W9NB,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208082,7/3/2012,,https://www.federalregister.gov/documents/2019/05/13/2019-09805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-austedo,5/29/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/3/2017,1735,675,,1,,,,,1,1,,,[2H]C([2H])([2H])OC1=C(OC([2H])([2H])[2H])C=C2[C@@H]3CC(=O)[C@@H](CC(C)C)CN3CCC2=C1,3.43446321,First deuterated drug approval,chorea associated with Huntington's disease,,,For the treatment of chorea associated with Huntington's disease,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000OtherR.pdf
761055,Dupixent,dupilumab,420K487FSG,Dermatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055,10/10/2009,,https://www.federalregister.gov/documents/2018/10/17/2018-22566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dupixent,7/29/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/28/2017,2726,242,1,,,1,1,,,,,,,,,eczema,Inhibitor,interleukin-4 receptor alpha,To treat adults with moderate-to-severe eczema (atopic dermatitis),
761053,Ocrevus,ocrelizumab,A10SJL62JY,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053,12/25/2003,,https://www.federalregister.gov/documents/2018/10/18/2018-22699/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocrevus,4/28/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/28/2017,4842,334,1,,1,1,1,,,,,,,,,multiple sclerosis,,,To treat patients with relapsing and primary progressive forms of multiple sclerosis,
208447,Zejula,niraparib,HMC2H89N35,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208447,5/21/2008,,https://www.federalregister.gov/documents/2019/02/12/2019-02036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zejula,10/31/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/27/2017,3232,147,,1,1,1,1,,,,,,NC(=O)C1=CC=CC2=CN(N=C12)C3=CC=C(C=C3)[C@@H]4CCCNC4,2.54360814,,peritoneal cancer,Inhibitor,Poly [ADP-ribose] polymerase 1 and 2,"For the maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers",
208854,Symproic,naldemedine,03KSI6WLXH,Gastroenterology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208854,4/28/2010,,https://www.federalregister.gov/documents/2019/04/15/2019-07459/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symproic,3/23/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/23/2017,2521,365,,,,,,,,,,,CC(C)(NC(=O)C1=C(O)[C@@H]2OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]24[C@@]5(O)C1)=CC=C3O)C7=NC(=NO7)C8=CC=CC=C8,2.42218774,,opioid-induced constipation,,,For the treatment of opioid-induced constipation,
761049,Bavencio,avelumab,KXG2PJ551I,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761049,12/13/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000MultidisciplineR.pdf,9/23/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/23/2017,1561,181,,1,1,1,1,1,,,,,,,First treatment for rare form of skin cancer,Merkel cell carcinoma,,,To treat metastatic Merkel cell carcinoma,
207145,Xadago,safinamide,90ENL74SIG,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207145,6/26/2003,,https://www.federalregister.gov/documents/2019/02/12/2019-02044/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xadago,12/29/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/21/2017,5017,813,,,,,,,1,,,,C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O,2.51452883,First innovative drug for PD-related motor fluctuations in more than a decade,complications of Parkinson's disease,Blocker|Inhibitor,Monoamine oxidase B|Sodium channel alpha subunit|glutamate secretion,To treat complications of Parkinson's disease,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207145Orig1s000ltr.pdf
209092,Kisqali,ribociclib,TK8ERE8P56,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,8/26/2010,,https://www.federalregister.gov/documents/2019/06/11/2019-12305/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kisqali,8/29/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/13/2017,2391,196,,,,1,1,,,,,,CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2)N1C5CCCC5,2.48901795,,breast cancer,Inhibitor,Cyclin-dependent kinase 4 and 6,To treat postmenopausal women with a type of advanced breast cancer,
208794,Xermelo,telotristat ethyl,8G388563M7,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208794,1/20/2008,,https://www.federalregister.gov/documents/2018/12/28/2018-28218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xermelo,3/30/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/28/2017,3327,335,1,1,1,,1,,,,,,CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C2=NC(N)=NC(O[C@H](C3=C(C=C(Cl)C=C3)N4C=CC(C)=N4)C(F)(F)F)=C2,5.61522769,First tryptophan hydroxylase inhibitor,carcinoid syndrome diarrhea,Inhibitor,tryptophan hydroxylase 1,To treat carcinoid syndrome diarrhea,
761032,Siliq,brodalumab,6ZA31Y954Z,Dermatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761032,8/22/2008,,https://www.federalregister.gov/documents/2018/10/23/2018-23058/determination-of-regulatory-review-period-for-purposes-of-patent-extension-siliq,11/16/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/15/2017,3099,457,,,,,,,,,,,,,First IL-17 receptor antagonist,psoriasis,Antagonist,interleukin-17 receptor,To treat adults with moderate-to-severe plaque psoriasis,
208684,Emflaza,deflazacort,KR5YZ6AE4B,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684%2C208685Orig1s000TOC.cfm,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684%2C208685Orig1s000StatR.pdf,6/9/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/9/2017,NA,245,1,1,1,,1,,,,,,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C,1.72334458,US approval of established corticosteroid therapy for Duchenne muscular dystrophy,Duchenne muscular dystrophy,Agonist,glucocorticoid receptor,To treat patients age 5 years and older with Duchenne muscular dystrophy (DMD),
208325,Parsabiv,etelcalcetide,60ME133FJB,Endocrinology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208325,9/19/2010,,https://www.federalregister.gov/documents/2018/12/28/2018-28221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-parsabiv,8/24/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/7/2017,2333,533,,,,,,,1,,,,,,,hyperparathyroidism,,,To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208325Orig1s000SumR.pdf
208745,Trulance,plecanatide,7IK8Z952OK,Gastroenterology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208745,5/2/2008,,https://www.federalregister.gov/documents/2018/12/04/2018-26289/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trulance,1/29/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/19/2017,3184,356,,,,,,,,,,,,,,chronic idiopathic constipation,,,To treat Chronic Idiopathic Constipation (CIC) in adult patients,
209531,Spinraza,nusinersen,5Z9SP3X666,Neurology,oligonucleotide,oligo,antisense oligo,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209531,10/1/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209531Orig1s000Admincorres.pdf,9/23/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/23/2016,2275,91,1,1,1,,1,,,,,,,,,spinal muscular atrophy,,,To treat children and adults with spinal muscular atrophy (SMA),
209115,Rubraca,rucaparib,8237F3U7EH,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,9/25/2009,,https://www.federalregister.gov/documents/2018/12/28/2018-28217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rubraca,6/23/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/19/2016,2642,179,,1,,1,1,1,,,,,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(F)=CC(N2)=C34,2.4648276,,ovarian cancer,Inhibitor,"PARP 1, 2 and 3",To treat women with a certain type of ovarian cancer,
207695,Eucrisa,crisaborole,Q2R47HGR7P,Dermatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207695,5/31/2008,,https://www.federalregister.gov/documents/2019/02/12/2019-01956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eucrisa,1/7/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/14/2016,3119,342,,,,,,,,,,,OB1OCC2=C1C=CC(OC3=CC=C(C=C3)C#N)=C2,3.3417,,eczema,Inhibitor,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A and 4B",To treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older,
125603,MACI,pork collagen,I8442U2G7J,Orthopedics,protein,protein,protein,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane,NA,Ex-US clinical development predates IND,https://wayback.archive-it.org/7993/20190425002036/https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM536121.pdf,1/4/2016,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane,12/13/2016,NA,344,,,,,,,,,,,,,,,,,"Repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults",
761046,Zinplava,bezlotoxumab,4H5YMK1H2E,Antibacterial,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761046_toc.cfm,11/25/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761046Orig1s000MedR.pdf,11/23/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/21/2016,3983,333,1,,1,,1,,,,,,,,,Clostridium difficile,,,To reduce the recurrence of Clostridium difficile infection in patients aged 18 years or older,
761038,Lartruvo,olaratumab,TT6HN20MVF,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761038,6/30/2006,,https://www.federalregister.gov/documents/2018/10/24/2018-23219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lartruvo,2/24/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/19/2016,3764,238,,1,1,1,1,1,,,,,,,,soft tissue sarcoma,,,To treat adults with certain types of soft tissue sarcoma,
206488,Exondys 51,eteplirsen,AIW6036FAS,Neurology,oligonucleotide,oligo,antisense oligo,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_TOC.cfm,10/26/2007,,https://clinicaltrials.gov/ct2/show/NCT00159250,6/26/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/19/2016,3251,451,1,1,1,,1,1,,,,,,,First drug for Duchenne muscular dystrophy,Duchenne muscular dystrophy,,,To treat patients with Duchenne muscular dystrophy,
208471,Adlyxin,lixisenatide,74O62BB01U,Endocrinology,protein,peptide,peptide,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208471,7/8/2001,,https://www.federalregister.gov/documents/2018/12/26/2018-27805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adlyxin,7/27/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/27/2016,5498,366,,,,,,,,,,,,,,type 2 diabetes mellitus,,,To improve glycemic control (blood sugar levels),
208073,Xiidra,lifitegrast,038E5L962W,Opthamology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208073,7/1/2008,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000MedR.pdf,2/25/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/11/2016,2932,502,1,,,,1,,1,,,,CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1,3.99291136,First-in-class LFA-1 antagonist,dry eye disease,antagonist,lymphocyte function-associated antigen 1,To treat the signs and symptoms of dry eye disease,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000CrossR.pdf
208341,Epclusa,velpatasvir,KCU0C7RS7Z,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208341,11/6/2012,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208341Orig1s000MedR.pdf,10/28/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/28/2016,1330,244,,,1,1,1,,,,,,COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C,4.95689731,,hepatitis C,Inhibitor,Nonstructural protein 5A,To treat all six major forms of hepatitis C virus,
208547,NETSPOT,gallium 68 dotatate,9L17Y0H71P,Oncology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208547,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208547Orig1s000MedR.pdf,7/1/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/1/2016,NA,336,,1,,,1,,,,1,,,,,neuroendocrine tumor diagnostic,,,A diagnostic imaging agent to detect rare neuroendocrine tumors,
207999,Ocaliva,obeticholic acid,0462Z4S4OZ,Gastroenterology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207999,3/1/2006,,https://www.federalregister.gov/documents/2018/12/04/2018-26288/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocaliva,6/29/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/27/2016,3740,333,1,1,1,,1,1,,,,,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]4(C)CC[C@@H](O)C[C@@H]14,4.47126502,,chronic liver disease,Agonist,Bile acid receptor FXR,"To treat rare, chronic liver disease",
761029,Zinbryta,daclizumab,CUJ2MVI71Y,Neurology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761029,NA,Biosimilar,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761029Orig1s000MedR.pdf,2/27/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/27/2016,NA,455,1,,,,,,,1,,,,,,multiple sclerosis,,,To treat multiple sclerosis,
208054,Axumin,fluciclovine F 18,38R1Q0L1ZE,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208054,6/10/2005,,https://www.federalregister.gov/documents/2018/01/17/2018-00684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axumin,9/28/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/27/2016,4004,242,,,,,1,,,,1,,N[C@]1(C[C@H]([18F])C1)C(O)=O,-2.0745278,,prostate cancer diagnostic,,,A new diagnostic imaging agent to detect recurrent prostate cancer,
761034,Tecentriq,atezolizumab,52CMI0WC3Y,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,5/11/2011,,https://www.federalregister.gov/documents/2018/10/22/2018-22957/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecentriq,1/12/2016,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/18/2016,1834,127,,,,1,1,1,,,,,,,,urothelial carcinoma,,,To treat urothelial carcinoma- the most common type of bladder cancer,
207318,Nuplazid,pimavanserin,JZ963P0DIK,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207318,11/9/2003,,https://www.federalregister.gov/documents/2018/10/23/2018-23057/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuplazid,9/1/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/29/2016,4555,241,,,,1,1,,,1,,,CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1,3.94992806,First drug to treat hallucinations and delusions associated with Parkinson's disease,,Inverse Agonist,Serotonin 2a (5-HT2a) receptor,To treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease,
208573,Venclexta,venetoclax,N54AIC43PW,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208573,11/28/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000MedR.pdf,10/29/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/11/2016,1961,165,1,1,,1,1,1,,,,,CC1(C)CCC(CN2CCN(CC2)C3=CC(OC4=CC5=C(NC=C5)N=C4)=C(C=C3)C(=O)NS(=O)(=O)C6=CC(=C(NCC7CCOCC7)C=C6)[N+]([O-])=O)=C(C1)C8=CC=C(Cl)C=C8,7.49048299,First-in-class BCL-2 inhibitor,chronic lymphocytic leukemia,Inhibitor,Apoptosis regulator Bcl-2,For chronic lymphocytic leukemia in patients with a specific chromosomal abnormality,
208114,Defitelio,defibrotide sodium,L7CHH2B2J0,Hematology,polymer,polymer,polydisperse oligonucleotide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208114,6/15/1997,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208114Orig1s000MedR.pdf,7/31/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/30/2016,6863,243,1,1,1,,1,,,,,,,,First drug for severe hepatic veno-occlusive disease,severe hepatic veno-occlusive disease,,,To treat adults and children who develop hepatic veno-occlusive disease with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation,
761033,Cinqair,reslizumab,35A26E427H,Respiratory,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761033,9/18/1997,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761033Orig1s000ClinPharmR.pdf,3/30/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/23/2016,6761,359,,,,,,,,1,,,,,,severe asthma,,,To treat severe asthma,
125521,Taltz,ixekizumab,BTY153760O,Rheumatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521,12/1/2007,,https://www.federalregister.gov/documents/2018/10/26/2018-23438/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taltz,3/23/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/22/2016,3034,365,,,,,,,,,,,,,,psoriasis,,,To treat adults with moderate-to-severe plaque psoriasis.,
125509,Anthim,obiltoxaximab,29Z5DNL48C,Antibacterial,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125509,8/4/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125509Orig1s000MedR.pdf,3/20/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/18/2016,3879,364,,1,1,,,,,1,,1,,,,inhalational anthrax,,,To treat inhalational anthrax in combination with appropriate antibacterial drugs.,
205836,Briviact,brivaracetam,U863JGG2IA,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205836,8/12/2004,,https://www.federalregister.gov/documents/2019/12/12/2019-26812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-injection-new,11/24/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/18/2016,4207,451,,,,,,,,,,,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1,0.63122823,,partial onset seizures,Modulator,Synaptic vesicle glycoprotein 2A,To treat partial onset seizures in patients age 16 years and older with epilepsy.,
208261,Zepatier,elbasvir|grazoprevir,632L571YDK|4O2AB118LA,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208261,6/28/2009,,https://www.pmda.go.jp/drugs/2016/P20161013003/170050000_22800AMX00710_K101_1.pdf,5/28/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/28/2016,2405,245,,,,1,1,,,,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=CC(=CC=C6C5=C4)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C9=CC=CC=C9,6.03495709,,hepatitis C,Inhibitor,"NS5A, Hepatitis C virus",To treat patients with chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.,
207988,Zurampic,lesinurad,09ERP08I3W,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207988,10/31/2009,,https://www.federalregister.gov/documents/2018/01/22/2018-00992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zurampic,12/29/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/22/2015,2243,358,,,,,,,,1,,,OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4,4.15170907,,gout,Inhibitor,Solute carrier family 22 member 11 and 12,To treat high blood uric acid levels associated with gout,
207947,Uptravi,selexipag,5EXC0E384L,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207947,10/29/2009,,https://www.federalregister.gov/documents/2018/01/30/2018-01637/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uptravi,12/22/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/21/2015,2244,364,,1,,,,,,,,,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3,3.65921693,,pulmonary arterial hypertension,Agonist|Inhibitor,Prostanoid IP receptor,To treat pulmonary arterial hypertension,
22225,Bridion,sugammadex,361LPM2T56,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022225,4/13/2004,,https://www.federalregister.gov/documents/2018/02/15/2018-03137/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bridion,10/31/2007,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/15/2015,4263,2967,1,,,,1,,1,,,,O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(O)=O)[C@@H](O[C@H]4O[C@H](CSCCC(O)=O)[C@@H](O[C@H]5O[C@H](CSCCC(O)=O)[C@@H](O[C@H]6O[C@H](CSCCC(O)=O)[C@@H](O[C@H]7O[C@H](CSCCC(O)=O)[C@@H](O[C@H]8O[C@H](CSCCC(O)=O)[C@@H](O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O[C@H]1O[C@@H]2CSCCC(O)=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,-4.8671803,First drug approved in new class of medications,,Binding Agent,rocuronium and vecuronium,To reverse effects of neuromuscular blocking drugs used during surgery,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000AdminCorres.pdf
208434,Alecensa,alectinib,LIJ4CT1Z3Y,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434,10/28/2011,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000SumR.pdf,7/6/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/11/2015,1505,158,,1,,1,1,1,,,,,CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6,4.87792787,,lung cancer,Inhibitor,ALK tyrosine kinase receptor,To treat ALK-positive lung cancer,
125561,Kanuma,sebelipase alfa,K4YTU42T8G,Hepatology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125561,12/22/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125561Orig1s000MedR.pdf,1/8/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/8/2015,1812,334,1,1,1,1,1,,,,,,,,First drug for lysosomal acid lipase (LAL) deficiency,lysosomal acid lipase (LAL) deficiency,,,To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiency,
761035,Empliciti,elotuzumab,1351PE5UGS,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761035,8/11/2006,,https://www.federalregister.gov/documents/2017/01/09/2017-00108/determination-of-regulatory-review-period-for-purposes-of-patent-extension-empliciti,6/29/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/30/2015,3398,154,1,1,,1,1,,,,,,,,Second monoclonal antibody for multiple myeloma,multiple myeloma,,,To treat people with multiple myeloma who have received one to three prior medications,
125547,Portrazza,necitumumab,2BT4C47RUI,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125547,12/19/2008,,https://www.federalregister.gov/documents/2018/02/20/2018-03345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-portrazza,12/2/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/24/2015,2531,357,,1,1,,,,,1,,,,,,squamous non-small cell lung cancer,,,To treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer,
208462,Ninlaro,ixazomib,71050168A2,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208462,12/10/2008,,https://www.federalregister.gov/documents/2018/01/22/2018-00994/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ninlaro,7/10/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/20/2015,2536,133,,1,,,1,,,,,,CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O,2.5677,,multiple myeloma,Inhibitor,Proteasome subunit beta type-5,To treat people with multiple myeloma who have received at least one prior therapy,
761036,Darzalex,daratumumab,4Z63YK6E0E,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036,7/28/2010,,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,7/9/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/16/2015,1937,130,1,1,1,1,1,1,,,,,,,First monoclonal antibody for multiple myeloma,multiple myeloma,,,To treat patients with multiple myeloma who have received at least three prior treatments.,
208065,Tagrisso,osimertinib,3C06JJ0Z2O,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,3/4/2013,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000SumR.pdf,6/5/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/13/2015,984,161,,1,1,1,1,1,,,,,COC1=C(NC2=NC=CC(=N2)C3=CN(C)C4=C3C=CC=C4)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C,4.52314177,,non-small cell lung cancer,Inhibitor,Epidermal growth factor receptor,To treat certain patients with non-small cell lung cancer,
206192,Cotellic,cobimetinib,ER29L26N1X,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192,1/19/2007,,https://www.federalregister.gov/documents/2018/02/16/2018-03218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cotellic,12/11/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/10/2015,3217,334,,1,1,,1,,,,,,OC1(CN(C1)C(=O)C2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3F)[C@@H]4CCCCN4,5.22095724,,melanoma,Inhibitor,Dual specificity mitogen-activated protein kinase kinase 1,"To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)",
207561,Genvoya,tenofovir alafenamide fumarate,FWF6Q91TZO,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207561,1/28/2002,,https://www.federalregister.gov/documents/2018/02/07/2018-02403/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genvoya,11/5/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/5/2015,5029,365,,,1,,,,,1,,,CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OC3=CC=CC=C3,1.91992613,,HIV-1,,,For the treatment of HIV-1 infection,
125526,Nucala,mepolizumab,90Z2UF0E52,Respiratory,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125526,1/22/1997,,https://www.federalregister.gov/documents/2016/12/13/2016-29838/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nucala,11/4/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/4/2015,6860,365,1,,,,,,,,,,,,,asthma,,,For use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older.,
125518,Imlygic,talimogene laherparepvec,07730V90L6,Oncology,oncolytic virus,virus,virus,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic-talimogene-laherparepvec,5/25/2005,,https://www.federalregister.gov/documents/2016/12/28/2016-31322/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imlygic,7/28/2014,https://wayback.archive-it.org/7993/20190425013447/https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM473103.pdf,10/27/2015,3807,456,1,,,,,,,,,,,,First oncolytic virus cancer therapy,melanoma,,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery",
207953,Yondelis,trabectedin,ID0YZQ2TCP,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207953,5/10/1996,,https://www.federalregister.gov/documents/2017/11/28/2017-25683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yondelis,11/24/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/23/2015,7105,333,,1,,,1,,,,,,COC1=CC2=C(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=CC(C)=C(OC)C(O)=C67)[C@H](O)N5[C@@H](COC3=O)C8=C9OCOC9=C(C)C(OC(C)=O)=C48)C=C1O,4.30396282,,soft tissue sarcoma,Binding Agent,DNA,To treat specific soft tissue sarcomas (STS) liposarcoma and leiomyosarcoma that cannot be removed by surgery (unresectable) or is advanced (metastatic).,https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/fda-issues-complete-response-letter-trabectedin-combined-doxil
125513,Strensiq,asfotase alfa,Z633861EIM,Endocrinology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125513,7/3/2008,,https://www.federalregister.gov/documents/2018/02/09/2018-02588/determination-of-regulatory-review-period-for-purposes-of-patent-extension-strensiq,12/23/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/23/2015,2668,304,1,1,1,1,1,,,,,,,,First approved treatment for hypophosphatasia,Hypophosphatasia (HPP),,,"To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).",
205739,Veltassa,patiromer,1FQ2RY5YHH,Endocrinology,polymer,polymer,polymer,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205739,1/9/2008,,https://www.federalregister.gov/documents/2017/11/29/2017-25761/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veltassa,10/21/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/21/2015,2842,365,,,,,,,,1,,,,,,hyperkalemia,,,"To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.",
761025,Praxbind,idarucizumab,97RWB5S1U6,Hematology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/0761025Orig1000TOC.cfm,9/1/2012,,https://clinicaltrials.gov/ct2/show/NCT01688830,2/19/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/16/2015,1140,239,1,1,,1,1,1,,,,,,,First reversal agent for the anticoagulant Pradaxa,anticoagulant emergency,,,For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.,
207533,Aristada,aripiprazole lauroxil,B786J7A343,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207533,7/16/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207533Orig1s000MedR.pdf,8/22/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/5/2015,1907,409,,,,,,,,1,,,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(OCCCCN3CCN(CC3)C4=C(Cl)C(Cl)=CC=C4)C=C2,9.36355931,,schizophrenia,Antagonist|Partial Agonist,Dopamine D2 receptor|Serotonin 1a (5-HT1a) receptor|Serotonin 2a (5-HT2a) receptor,To treat adults with schizophrenia,
203314,Tresiba,insulin degludec,54Q18076QB,Endocrinology,protein,peptide,peptide,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313and203314Orig1s000TOC.cfm,10/5/2007,,https://www.federalregister.gov/documents/2016/12/02/2016-28939/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tresiba,9/29/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/25/2015,2912,1457,,,,,,,1,,,,,,,diabetes mellitus,,,To improve blood sugar (glucose) control in adults with diabetes mellitus,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313Orig1s000Approv.pdf
207981,Lonsurf,tipiracil,NGO10K751P,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207981,1/28/1999,,https://www.federalregister.gov/documents/2018/01/30/2018-01641/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lonsurf,12/19/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/22/2015,6081,277,,,1,,,,,,,,ClC1=C(CN2CCCC2=N)NC(=O)NC1=O,-1.3798726,,colorectal cancer,Inhibitor,Thymidine phosphorylase,To treat patients with an advanced form of colorectal cancer who are no longer responding to other therapies,
204370,Vraylar,cariprazine,F6RJL8B278,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig2s000TOC.cfm,6/21/2005,,https://www.federalregister.gov/documents/2018/01/26/2018-01368/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vraylar,11/19/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/17/2015,3740,1032,,,,,,,1,,,,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C3=CC=CC(Cl)=C3Cl)CC1,4.00158466,,"schizophrenia, bipolar disorder",Antagonist|Partial Agonist,Dopamine D2 receptor|Dopamine D3 receptor|Serotonin 1a (5-HT1a) receptor|Serotonin 2a (5-HT2a) receptor|Serotonin 2b (5-HT2b) receptor,To treat schizophrenia and bipolar disorder in adults,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000AdminCorres.pdf
208169,Xuriden,uridine triacetate,2WP61F175M,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208169,6/4/1992,,https://www.federalregister.gov/documents/2017/11/29/2017-25770/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xuriden,1/8/2015,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/4/2015,8492,239,1,1,,1,1,,,,,,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N2C=CC(=O)NC2=O,-1.1121151,First emergency treatment for overdose of certain types of chemotherapy,hereditary orotic aciduria,Interacts|Substrate,RNA|Uridine phosphorylase 1|Uridine-cytidine kinase|uridine phosphorylase 2,To treat patients with hereditary orotic aciduria,
206500,Varubi,rolapitant,NLE429IZUC,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206500,4/8/2007,,https://www.federalregister.gov/documents/2018/01/26/2018-01373/determination-of-regulatory-review-period-for-purposes-of-patent-extension-varubi,9/5/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/1/2015,3068,361,,,,,,,,,,,C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C3=CC=CC=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F,5.15021545,,chemotherapy-induced nausea and vomiting,Antagonist|Binding Agent,Neurokinin 1 receptor|Neurokinin 2 receptor|Neurokinin 3 receptor,To prevent delayed phase chemotherapy-induced nausea and vomiting (emesis),
125522,Repatha,evolocumab,LKC0U3A8NJ,Endocrinology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522,6/14/2009,,https://www.federalregister.gov/documents/2016/10/19/2016-25221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-repatha,8/27/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/27/2015,2265,365,,1,,,,,,,,,,,,high cholesterol,,,To treat certain patients with high cholesterol,
22526,Addyi,flibanserin,37JK4STR6Z,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022526,11/15/1996,,https://www.federalregister.gov/documents/2018/02/15/2018-03130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-addyi,10/27/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/18/2015,6850,2121,1,,,,,,1,,,,FC(F)(F)C1=CC=CC(=C1)N2CCN(CCN3C(=O)NC4=C3C=CC=C4)CC2,3.69971154,,hypoactive sexual desire disorder (HSDD),Agonist|Antagonist,Dopamine D4 receptor|Serotonin 1a (5-HT1a) receptor|Serotonin 2a (5-HT2a) receptor,"To treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000SumRedt.pdf
206843,Daklinza,daclatasvir,LI2427F9CI,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206843,11/17/2007,,https://www.federalregister.gov/documents/2018/01/17/2018-00675/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daklinza,3/31/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/24/2015,2806,480,,,1,,1,,1,,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C,4.05458429,,hepatitis C,Inhibitor,Nonstructural protein 5A,To treat chronic hepatitis C virus (HCV) genotype 3 infections,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206843Orig1s000SumR.pdf
205266,Odomzo,sonidegib,0RLU3VTK5M,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205266,12/15/2008,,https://www.federalregister.gov/documents/2018/02/09/2018-02658/determination-of-regulatory-review-period-for-purposes-of-patent-extension-odomzo,9/26/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/24/2015,2412,301,,,,,,,,1,,,C[C@H]1CN(C[C@@H](C)O1)C2=NC=C(NC(=O)C3=C(C)C(=CC=C3)C4=CC=C(OC(F)(F)F)C=C4)C=C2,6.73759334,,basal cell carcinoma,Antagonist,Smoothened homolog,"To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.",
125559,Praluent,alirocumab,PP0SHH6V16,Endocrinology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125559,11/12/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125559Orig1s000MedR.pdf,11/24/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/24/2015,2080,242,1,,,,1,,,,,,,,,high cholesterol,,,To treat certain patients with high cholesterol,
205422,Rexulti,brexpiprazole,2J3YBM1K8C,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205422,4/23/2008,,https://www.federalregister.gov/documents/2017/11/29/2017-25772/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rexulti,7/11/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/10/2015,2634,364,,,,,,,,1,,,O=C1NC2=C(C=C1)C=CC(OCCCCN3CCN(CC3)C4=CC=CC5=C4C=CS5)=C2,4.5785439,,schizophrenia,Antagonist|Partial Agonist,Alpha-1b adrenergic receptor|Alpha-2c adrenergic receptor|Dopamine D2 receptor|Dopamine D3 receptor|Serotonin 1a (5-HT1a) receptor|Serotonin 2a (5-HT2a) receptor|Serotonin 2b (5-HT2b) receptor,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder,
207620,Entresto,sacubitril,17ERJ0MKGI,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207620,11/25/2006,,https://www.federalregister.gov/documents/2018/02/09/2018-02592/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entresto,12/17/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/7/2015,3146,202,1,,1,,1,,,1,,,CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(O)=O,3.80991088,,heart failure,Inhibitor,Neprilysin,To treat heart failure,
206038,Orkambi,lumacaftor,EGP8L81APK,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206038,11/18/2007,,https://www.federalregister.gov/documents/2018/02/15/2018-03127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orkambi,11/5/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/2/2015,2783,239,1,1,1,1,1,,,,,,CC1=C(N=C(NC(=O)C2(CC2)C3=CC4=C(OC(F)(F)O4)C=C3)C=C1)C5=CC(=CC=C5)C(O)=O,5.7533767,,cystic fibrosis,Activator|Chaperone,Cytochrome P450 3A|F508del-CFTR,To treat cystic fibrosis,
204958,Kengreal,cangrelor,6AQ1Y404U7,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958,9/19/1998,,https://www.federalregister.gov/documents/2017/08/30/2017-18380/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kengreal,4/30/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/22/2015,6120,783,,,,,,,1,,,,CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1,-0.2534577,,prevention of blood clots,,,To prevent the formation of harmful blood clots in the coronary arteries for adult patients undergoing percutaneous coronary intervention,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204958Orig1s000Approv.pdf
206940,Viberzi,eluxadoline,45TPJ4MBQ1,Gastroenterology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206940,12/21/2007,,https://www.federalregister.gov/documents/2018/02/05/2018-02187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viberzi,6/27/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/27/2015,2714,334,,,1,,1,,,,,,COC1=C(C=C(CN([C@@H](C)C2=NC(=CN2)C3=CC=CC=C3)C(=O)[C@@H](N)CC4=C(C)C=C(C=C4C)C(N)=O)C=C1)C(O)=O,2.62303036,,irritable bowel syndrome with diarrhea (IBS-D),Agonist|Antagonist,Delta opioid receptor|Mu opioid receptor,To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.,
206333,Kybella,deoxycholic acid,005990WHZZ,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206333,12/5/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206333Orig1s000PharmR.pdf,5/13/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/29/2015,2702,351,,,,,,,,,,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,3.73831088,Repurposed drug for cosmetic surgery,submental fat,Agonist|Antagonist|Inhibitor,Bile acid receptor FXR|Formyl peptide receptor 1|G-protein coupled bile acid receptor 1|Staphylococcus aureus,"To treat adults with moderate-to-severe fat below the chin, known as submental fat",
206143,Corlanor,ivabradine,3H48L0LPZQ,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206143,NA,Ex-US clinical development predates IND,https://www.federalregister.gov/documents/2018/02/01/2018-01979/determination-of-regulatory-review-period-for-purposes-of-patent-extension-corlanor,6/27/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/15/2015,NA,292,1,,1,,1,,,,,,COC1=CC2=C(CC(=O)N(CCCN(C)C[C@H]3CC4=CC(OC)=C(OC)C=C34)CC2)C=C1OC,2.70619127,,heart failure,Blocker,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1|Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2|Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3|Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4,To reduce hospitalization from worsening heart failure.,
125562,Anthrasil,anthrax immune globulin human,VKZ83S945Z,Antibacterial,protein,antibody,antibody,BLA,https://wayback.archive-it.org/7993/20190423063458/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm441234.htm,2/23/2006,,https://wayback.archive-it.org/7993/20190423063458/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM567443.zip,3/10/2014,https://wayback.archive-it.org/7993/20190423063458/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM567443.zip,3/24/2015,3316,379,,1,,,1,,,,,1,,,,,,,Treatment of adult and pediatric patients with toxemia associated with inhalational anthrax.,
205750,Cholbam,cholic acid,G1JO7801AE,Gastroenterology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205750,6/5/1994,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205750Orig1s000AdminCorres.pdf,11/21/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/17/2015,7590,481,,1,,,1,,,,,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,2.40652609,,bile acid synthesis disorders,Agonist,Bile acid receptor FXR,"To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders",
125516,Unituxin,dinutuximab,7SQY4ZUD30,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125516,12/4/1991,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125516Orig1s000MedR.pdf,4/11/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/10/2015,8497,333,1,1,,,1,,,1,,,,,,neuroblastoma,,,To treat pediatric patients with high-risk neuroblastoma,
207500,Cresemba,isavuconazonium sulfate,31Q44514JV,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207500,7/10/2005,,https://www.federalregister.gov/documents/2018/01/31/2018-01892/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cresemba-new-drug,7/8/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/6/2015,3526,241,,1,,,1,,,,,,CNCC(=O)OCC1=CC=CN=C1N(C)C(=O)OC(C)[N+]2=CN(C[C@@](O)([C@@H](C)C3=NC(=CS3)C4=CC=C(C=C4)C#N)C5=CC(F)=CC=C5F)N=C2,1.1812175,,"invasive aspergillosis, invasive mucormycosis",Inhibitor,Lanosterol 14-alpha demethylase,"To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections",
206494,Avycaz,avibactam,7352665165,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206494,2/5/2008,,https://www.federalregister.gov/documents/2018/01/17/2018-00678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avycaz,6/25/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/25/2015,2577,245,,,1,,1,,,,,,NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O,-3.6277908,,urinary tract infections,Inhibitor,Bacterial beta-lactamase TEM,"To treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.",
205353,Farydak,panobinostat,9647FM7Y3Z,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205353,4/15/2003,,https://www.federalregister.gov/documents/2018/02/13/2018-02868/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farydak,3/24/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/23/2015,4332,336,,1,,,1,1,,1,,,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C(N1)C=CC=C3,2.54428561,,myeloma,Inhibitor,Histone deacetylase 1|Histone deacetylase 2|Histone deacetylase 3|Histone deacetylase 4|Histone deacetylase 6|Histone deacetylase 8,To treat patients with multiple myeloma,
206947,Lenvima,lenvatinib,EE083865G2,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206947,4/28/2005,,https://www.federalregister.gov/documents/2018/01/31/2018-01920/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lenvima,8/14/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/13/2015,3578,183,,1,,,1,,,,,,COC1=C(C=C2C(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=CC=NC2=C1)C(N)=O,2.48596348,,differentiated thyroid cancer (DTC),Antagonist,Fibroblast growth factor receptor 1|Fibroblast growth factor receptor 2|Fibroblast growth factor receptor 3|Platelet-derived growth factor receptor beta|Stem cell growth factor receptor|Vascular endothelial growth factor receptor 1|Vascular endothelial growth factor receptor 2|Vascular endothelial growth factor receptor 3,"To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).",
207103,Ibrance,palbociclib,G9ZF61LE7G,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,4/9/2004,,https://www.federalregister.gov/documents/2018/02/14/2018-03029/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ibrance,8/13/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/3/2015,3952,174,1,,,1,1,1,,,,,CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2)N(C5CCCC5)C1=O,2.77525835,,advanced (metastatic) breast cancer,Inhibitor,CDK4/Cyclin D3|CDK6/cyclin D2|Cyclin-dependent kinase 4/cyclin D1|MDA-MB-175-VII|ZR-75-30,To treat advanced (metastatic) breast cancer,
125511,Natpara,parathyroid hormone,N19A0T0E5J,Endocrinology,protein,peptide,peptide,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511,3/3/1995,,https://www.federalregister.gov/documents/2017/06/15/2017-12359/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natpara,10/24/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/23/2015,7266,456,,1,,,,,,,,,,,,hypocalcemia,,,To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism,
125504,Cosentyx,secukinumab,DLG4EML025,Dermatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504,10/21/2005,,https://www.federalregister.gov/documents/2016/12/20/2016-30528/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cosentyx,10/24/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/21/2015,3379,454,1,,,,,,,,,,,,,plaque psoriasis,,,To treat adults with moderate-to-severe plaque psoriasis,
206316,Savaysa,edoxaban,NDU3J18APO,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206316,7/1/2004,,https://www.federalregister.gov/documents/2017/11/28/2017-25703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-savaysa,1/8/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/8/2015,3843,365,,,,,,,,1,,,CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C3=NC4=C(CN(C)CC4)S3,0.85032969,,patients at risk for systemic embolism,Inhibitor,Coagulation factor X,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem,
125554,Opdivo,nivolumab,31YO63LBSN,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,7/28/2006,,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,7/30/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/22/2014,3069,145,,1,1,1,1,1,,,,,,,Pembrolizumab and Nivolumab are first to target PD-1,"unresectable melanoma, metastatic melanoma",Inhibitor,PD-1,To treat patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugs,
206162,Lynparza,olaparib,WOH1JD9AR8,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206162,7/4/2005,,https://clinicaltrials.gov/ct2/show/NCT00516373,2/3/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/19/2014,3455,319,1,1,,,1,1,,,,,FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5,1.93714854,First inhibitor approved against PARP,,Inhibitor,Poly [ADP-ribose] polymerase 1|Poly [ADP-ribose] polymerase 2|Poly [ADP-ribose] polymerase 3,To treat advanced ovarian cancer,
206829,Zerbaxa,ceftolozane,37A4IES95Q,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206829,7/5/2008,,https://www.federalregister.gov/documents/2017/11/28/2017-25682/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zerbaxa,4/21/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/19/2014,2358,242,,,1,,1,,,,,,CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC2=C(N3[C@H](SC2)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C4=NSC(N)=N4)C3=O)C([O-])=O,-7.2439975,,urinary tract infections,Inhibitor,Bacterial penicillin-binding protein,To treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI),
206619,Viekira Pak,ombitasvir|paritaprevir|dasabuvir,2302768XJ8|OU2YM37K86|DE54EQW8T1,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206619,6/4/2008,,https://www.federalregister.gov/documents/2018/01/30/2018-01651/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viekira-pak,4/21/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/19/2014,2389,242,1,,1,1,1,,,,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)C=C5,7.34311017,,hepatitis C,Inhibitor,Nonstructural protein 5A,"To treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis",
206426,Rapivab,peramivir,QW7Y7ZR15U,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206426,12/21/2005,,https://www.federalregister.gov/documents/2017/11/28/2017-25676/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapivab,12/23/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/19/2014,3285,361,,,1,,,,,,,,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O,-1.4879923,,influenza,Inhibitor,Influenza A virus infection,To treat influenza infection in adults,
206307,Xtoro,finafloxacin,D26OSN9Q4R,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206307,8/2/2007,,https://clinicaltrials.gov/ct2/show/NCT00483158,4/25/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/17/2014,2694,236,,,,,1,,,,,,OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O,-0.3443974,,,Inhibitor,DNA gyrase subunit A|DNA topoisomerase IV subunit A,"To treat acute otitis externa, commonly known as swimmer's ear",
125557,Blincyto,blinatumomab,4FR53SIF3A,Oncology,protein,antibody,bispecific antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557,6/1/2004,,https://clinicaltrials.gov/ct2/show/NCT00274742,9/19/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/3/2014,3837,75,1,1,,1,1,1,,1,,,,,First bispecific antibody approval (CD19-CD3),,,CD19 and CD3 targeted,To treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL),
22535,Esbriet,pirfenidone,D7NLD2JX7U,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022535,9/29/1973,,https://www.federalregister.gov/documents/2018/02/22/2018-03612/determination-of-regulatory-review-period-for-purposes-of-patent-extension-esbriet,11/4/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/15/2014,14991,1806,1,1,1,1,1,,1,,,,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,2.07755532,novel; systemic antifibrotic activity,,,,For the treatment of idiopathic pulmonary fibrosis (IPF),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000Approv.pdf
205832,Ofev,nintedanib,G6HRD2P839,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205832,11/1/2002,,https://clinicaltrials.gov/ct2/show/NCT01951846,5/2/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/15/2014,4366,166,1,1,1,1,1,,,,,,COC(=O)C1=CC2=C(C=C1)\C(C(=O)N2)=C(\NC3=CC=C(C=C3)N(C)C(=O)CN4CCN(C)CC4)C5=CC=CC=C5,2.69673606,,,Inhibitor,Vascular endothelial growth factor receptor 1|Vascular endothelial growth factor receptor 2|Vascular endothelial growth factor receptor 3,For the treatment of idiopathic pulmonary fibrosis (IPF),
203684,Lumason,sulfur hexafluoride,WS7LR3I1D6,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203684,1/26/1995,,https://www.federalregister.gov/documents/2016/09/16/2016-22345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumason,12/21/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/10/2014,7197,1024,,,,,,,1,1,1,,FS(F)(F)(F)(F)F,2.38690982,,,,,For patients whose ultrasound image of the heart (echocardiograms) are hard to see with ultrasound waves,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000ODMemo.pdf
205718,Akynzeo,netupitant,7732P08TIR,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205718,9/14/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000MedR.pdf,9/27/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/10/2014,2948,378,,,,,,,,,,,CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C2=C(C=C(N=C2)N3CCN(C)CC3)C4=C(C)C=CC=C4,7.22548098,,,Antagonist,Substance-P receptor,To treat nausea and vomiting in patients undergoing cancer chemotherapy,
205834,Harvoni,ledipasvir,013TE6E4WV,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205834,4/30/2010,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000MedR.pdf,2/10/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/10/2014,1624,242,1,,1,1,1,,,,,,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC=C(C=C6C5(F)F)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]%10CC[C@H](C%10)N9C(=O)[C@@H](NC(=O)OC)C(C)C,6.50536309,,hepatitis C,Inhibitor,Nonstructural protein 5A,To treat chronic hepatitis C virus (HCV) genotype 1 infection,
125469,Trulicity,dulaglutide,WTT295HSY5,Endocrinology,protein,peptide,peptide,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469,9/4/2005,,https://www.federalregister.gov/documents/2016/12/19/2016-30399/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trulicity,9/18/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/18/2014,3301,365,,,,,,,,1,,,,,,,Agonist,GLP-1 receptor,To treat adults with type 2 diabetes.,
204760,Movantik,naloxegol,44T7335BKE,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204760,11/21/2007,,https://www.federalregister.gov/documents/2018/02/16/2018-03245/determination-of-regulatory-review-period-for-purposes-of-patent-extension-movantik,9/16/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/16/2014,2491,365,,,,,,,,,,,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4,1.57142013,Incremental improvement; PEGlated naloxone,,Antagonist,Mu-type opioid receptor,To treat opioid-induced constipation in adults with chronic non-cancer pain.,
125514,Keytruda,pembrolizumab,DPT0O3T46P,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,1/7/2011,,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,2/27/2014,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/4/2014,1336,189,1,1,,1,1,1,,,,,,,Pembrolizumab and Nivolumab are first to target PD-1,,Inhibitor,PD-1,For treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.,
205494,Cerdelga,eliglustat,DR40J4WA67,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205494,2/1/2004,,https://www.federalregister.gov/documents/2016/11/22/2016-28045/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerdelga,9/20/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/19/2014,3852,333,,1,,,1,,,,,,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2,3.24158534,,,Antagonist,Ceramide glucosyltransferase,For the long-term treatment of adult patients with the Type 1 form of Gaucher disease,
125499,Plegridy,peginterferon beta-1a,I8309403R0,Neurology,protein,protein,PEGlated protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125499,5/23/2007,,https://www.federalregister.gov/documents/2016/10/19/2016-25222/determination-of-regulatory-review-period-for-purposes-of-patent-extension-plegridy,5/16/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/15/2014,2641,456,,,,,,,,,,,,,Incremental Improvement; PEGlated interferon beta-1a,,,,For the treatment of patients with relapsing forms of multiple sclerosis,
204569,Belsomra,suvorexant,081L192FO9,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569,5/7/2008,,https://www.federalregister.gov/documents/2018/02/12/2018-02763/determination-of-regulatory-review-period-for-purposes-of-patent-extension-belsomra,8/30/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/13/2014,2289,713,1,,,,,,1,,,,C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5,4.0394,novel; first approved against orexin receptor,,Antagonist,Orexin receptor type 1|Orexin receptor type 2,To treat difficulty in falling and staying asleep (insomnia),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569Orig1s000AdminCorres.pdf
206334,Orbactiv,oritavancin,PUG62FRZ2E,Antibacterial,chemical,peptide,glycopeptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206334,9/12/1996,,https://www.federalregister.gov/documents/2016/06/17/2016-14353/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orbactiv,12/6/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/6/2014,6537,243,,,,,1,,,,,,,,,,Inhibitor,Enterococcus faecium|Peptidoglycan|Staphylococcus aureus|Streptococcus pyogenes,To treat adults with skin infections,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000ODMemo.pdf
204629,Jardiance,empagliflozin,HDC1R2M35U,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204629,5/11/2008,,https://www.federalregister.gov/documents/2018/02/14/2018-02992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jardiance,3/5/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/1/2014,2273,514,,,,,,,1,,,,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(O[C@H]4CCOC4)C=C3)=C(Cl)C=C2,1.69083873,,,Antagonist,Sodium/glucose cotransporter 2,To improve gylcemic control in adults with type 2 diabetes,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000SumR.pdf
203108,Striverdi Respimat,olodaterol,VD2YSN1AFD,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203108,2/1/2005,,https://clinicaltrials.gov/ct2/show/NCT02171780,5/14/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/31/2014,3467,808,,,,,,,1,1,,,COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1,1.33165828,,,Agonist,Beta-2 adrenergic receptor,To treat chronic obstructive pulmonary disease,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203108Orig1s000AdminCorres.pdf
205858,Zydelig,idelalisib,YG57I8T5M0,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205858,5/30/2008,,https://www.federalregister.gov/documents/2018/02/23/2018-03701/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zydelig-new-drug,9/11/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/23/2014,2245,315,1,1,1,1,1,1,,1,,,CC[C@H](NC1=C2N=CNC2=NC=N1)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4,3.43423492,novel; first approved against this target,,Antagonist,PI3-kinase p110-delta subunit,"(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies; (3) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.",
204427,Kerydin,tavaborole,K124A4EUQ3,Antifungal,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204427,12/31/2005,,https://www.federalregister.gov/documents/2018/02/14/2018-02993/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kerydin,7/29/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/7/2014,3110,343,1,,,,,,,,,,OB1OCC2=C1C=CC(F)=C2,2.2372,,,Antagonist,ENTREZ Gene ID: 10373705|ENTREZ Gene ID: 10373871,For the topical treatment of onychomycosis of the toenails,
206256,Beleodaq,belinostat,F4H96P17NZ,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206256,12/16/2004,,https://www.federalregister.gov/documents/2018/02/14/2018-03041/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beleodaq,12/9/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/3/2014,3486,206,,1,1,,1,1,,,,,ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC2=CC=CC=C2,1.77875118,,,Inhibitor,Histone deacetylase 1|Histone deacetylase 3,To treat patients with peripheral T-cell lymphoma (PTCL),
205435,Sivextro,tedizolid phosphate,O7DRJ6R4DW,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205435,12/30/2007,,https://www.federalregister.gov/documents/2017/12/26/2017-27684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sivextro,10/21/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/20/2014,2364,242,,,,,1,,,,,,CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](COP(O)(O)=O)OC4=O,1.99603577,,,Antagonist|Inhibitor,Bacterial 70S ribosome,To treat adults with skin infections,
203567,Jublia,efinaconazole,J82SB7FXWB,Antifungal,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567_jublia_toc.cfm,7/14/2007,,https://www.federalregister.gov/documents/2018/02/08/2018-02522/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jublia,7/26/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/6/2014,2519,680,,,,,,,1,,,,C[C@@H](N1CCC(=C)CC1)[C@](O)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3,2.33557568,,,Inhibitor,Lanosterol 14-alpha demethylase,Treat mild to moderate onychomycosis (fungal infection),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000MedR.pdf
21883,Dalvance,dalbavancin,808UI9MS5K,Antibacterial,chemical,peptide,glycopeptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021883,8/13/2000,,https://www.federalregister.gov/documents/2018/02/12/2018-02768/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dalvance,12/21/2004,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/23/2014,5031,3440,,,1,,1,,1,,,,,,,,Inhibitor,Peptidoglycan,To treat adults with skin infections,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021883Orig1s000OtherActionLtrs.pdf
125476,Entyvio,vedolizumab,9RV78Q2002,Gastroenterology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125476,7/8/2000,,https://www.federalregister.gov/documents/2016/09/16/2016-22344/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entyvio,6/20/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/20/2014,5064,334,,,1,,1,,,,,,,,novel; targets Integrin Œ±4Œ≤7,,Antagonist,Integrin receptor,To treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn's disease,
204886,Zontivity,vorapaxar,ZCE93644N2,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204886,1/16/2005,,https://www.federalregister.gov/documents/2018/02/15/2018-03170/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zontivity,5/10/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/8/2014,3399,363,1,,1,,,,,1,,,CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\C4=NC=C(C=C4)C5=CC(F)=CC=C5)C1,4.96788789,novel target; PAR-1 antagonist,,Antagonist,Proteinase-activated receptor 1,To reduce the risk of heart attacks and stroke in high-risk patients,
205755,Zykadia,ceritinib,K418KG2GET,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205755,11/7/2010,,https://www.federalregister.gov/documents/2017/12/26/2017-27745/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zykadia,12/24/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/29/2014,1269,126,,1,,1,1,1,,,,,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC3=NC(NC4=C(C=CC=C4)S(=O)(=O)C(C)C)=C(Cl)C=N3,6.023663,,,Antagonist,ALK tyrosine kinase receptor,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,
125496,Sylvant,siltuximab,T4H8FMA7IM,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125496,8/1/1998,,https://www.nature.com/articles/6605872,8/30/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/23/2014,5744,236,1,1,,,1,,,,,,,,"novel target, but just upstream of Tocilizumab",,Inhibitor,Interleukin-6,"To treat patients with multicentric Castleman's disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes)",
125477,Cyramza,ramucirumab,D99YVK4L0X,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477,9/1/2004,,https://www.federalregister.gov/documents/2016/04/15/2016-08692/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cyramza,8/23/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/21/2014,3519,241,,1,1,,1,,,1,,,,,novel; VEGF and VEGFR1 anitbodies exist,,Inhibitor,VEGFR2,To treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma,
125431,Tanzeum,albiglutide,5E7U48495E,Endocrinology,protein,peptide,peptide,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125431,1/15/2006,,https://www.federalregister.gov/documents/2016/06/10/2016-13797/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tanzeum,1/14/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/15/2014,3012,456,,,,,,,,1,,,,,,,Agonist,GLP-1 receptor,"To improve glycemic control, along with diet and exercise, in adults with type 2 diabetes",
205437,Otezla,apremilast,UP7QBP99PN,Dermatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205437,8/28/2004,,https://www.federalregister.gov/documents/2016/06/01/2016-12829/determination-of-regulatory-review-period-for-purposes-of-patent-extension-otezla,3/21/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/21/2014,3492,365,1,,,,,,,,,,CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N2C(=O)C3=C(C2=O)C(NC(C)=O)=CC=C3,1.27828631,novel; no other PDE4 inhibitor seems to have activity in arthritis (Roflumilast is approved for COPD),,Inhibitor,Phosphodiesterase 4,To treat adults with active psoriatic arthritis (PsA),
204677,Neuraceq,florbetaben F 18,TLA7312TOI,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204677,10/1/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204677Orig1s000MedR.pdf,12/21/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/19/2014,2361,453,,,,,,,,,1,,CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1,3.72675353,novel; AD plaque imaging,PET imaging diagnostic,Binding Agent,Amyloid beta A4 protein,For Positron EmissionTomography (PET) imaging of the brain,
204684,Impavido,miltefosine,53EY29W7EC,Other Infectious disease,chemical,small molecule,lipid,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204684,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204684Orig1s000MedR.pdf,4/19/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/19/2014,NA,334,1,1,1,,1,,,,,,,,novel; various effects incl on AKT,,Antagonist,UNIPROT: B7TYN7,To treat a tropical disease called leishmaniasis,
125390,Myalept,metreleptin,TL60C27RLH,Endocrinology,protein,peptide,peptide,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390,5/2/1996,,https://www.federalregister.gov/documents/2016/09/23/2016-22935/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myalept,3/27/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/24/2014,6507,334,1,1,1,,1,,,1,,,,,novel; leptin not previously approved,,Agonist,Leptin receptor,To treat the complications of leptin deficiency,
203202,Northera,droxidopa,J7A92W69L7,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203202,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203202Orig1s000MedR.pdf,9/28/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/18/2014,NA,874,1,1,1,,1,1,1,1,,,N[C@@H]([C@H](O)C1=CC=C(O)C(O)=C1)C(O)=O,-1.941004,"Incremental improvement, BBB-penetrant prodrug/precursor",,Agonist,Adrenergic receptor,To treat neurogenic orthostatic hypotension (NOH),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203202Orig1s000AdminCorres.pdf
125460,Vimizim,elosulfase alfa,ODJ69JZG85,Endocrinology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125460,12/28/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125460Orig1s000StatR.pdf,3/29/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/14/2014,2240,322,1,1,1,,1,,,1,,,,,novel enzyme replacement therapy,,,,Treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome),
205677,Hetlioz,tasimelteon,SHS4PU80D9,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205677,3/16/1998,,https://www.federalregister.gov/documents/2017/06/14/2017-12323/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hetlioz,5/31/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/31/2014,5800,245,,1,,,1,,,,,,CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2,1.95706634,,,Agonist,Melatonin receptor type 1A|Melatonin receptor type 1B,To treat non-24-hour sleep-wake disorder in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep.,
202293,Farxiga,dapagliflozin,1ULL0QJ8UC,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202293,12/21/2003,,https://www.federalregister.gov/documents/2018/02/07/2018-02418/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farxiga,12/28/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/8/2014,3671,1107,,,,,,,1,,,,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1,2.13335385,,,Inhibitor,Sodium/glucose cotransporter 2,"To improve glycemic control, along with diet and exercise, in adults with type 2 diabetes",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000SumR.pdf
203975,Anoro Ellipta,umeclidinium,GE2T1418SV,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203975,8/14/2009,,https://www.federalregister.gov/documents/2016/03/01/2016-04370/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anoro-ellipta,12/18/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/18/2013,1587,365,,,,,,,,,,,OC(C1=CC=CC=C1)(C2=CC=CC=C2)C34CC[N+](CCOCC5=CC=CC=C5)(CC3)CC4,1.25973466,,,Antagonist,Muscarinic acetylcholine receptor M3,"For the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).",
204671,Sovaldi,sofosbuvir,WJ6CA3ZU8B,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204671,3/30/2009,,https://www.pmda.go.jp/drugs/2015/P20150615003/230867000_22700AMX00691_K100_1.pdf,4/8/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/6/2013,1712,242,1,,1,1,1,,,,,,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3,1.14693675,,hepatitis C,Inhibitor|Substrate,Acyl coenzyme A:cholesterol acyltransferase|Hepatitis C virus|Lysosomal protective protein,To treat chronic hepatitis C virus (HCV) infection.,
205123,Olysio,simeprevir,9WS5RD66HZ,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205123,12/18/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf,3/28/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/22/2013,2166,239,,,1,,1,,,,,,COC1=CC=C2C(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCCC=CC5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)=CC(=NC2=C1C)C7=NC(=CS7)C(C)C,4.52939841,,hepatitis C,Inhibitor,NS3/4A protease,To treat chronic hepatitis C virus infection.,
204153,Luzu,luliconazole,RE91AN4S8G,Antifungal,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204153,9/27/2007,,https://www.federalregister.gov/documents/2016/04/22/2016-09374/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luzu,12/11/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/14/2013,2240,338,,,,,,,,,,,ClC1=CC=C([C@@H]2CS\C(S2)=C(\C#N)N3C=CN=C3)C(Cl)=C1,4.14876777,,,,,"For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.",
205552,Imbruvica,ibrutinib,1X70OSD4VX,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205552,10/7/2008,,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,6/28/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/13/2013,1863,138,1,1,1,1,1,1,,,,,NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4,3.65625547,,mantle cell lymphoma,Inhibitor,Tyrosine-protein kinase BTK,"To treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.",
22416,Aptiom,eslicarbazepine acetate,BEA68ZVB2K,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022416,7/1/2000,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022416Orig1s000MedR.pdf,3/30/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/8/2013,4878,1684,,,,,,,1,,,,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C3=CC=CC=C13,2.11064321,,,Antagonist,Sodium channel alpha subunit,As an add-on medication to treat seizures associated with epilepsy.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022416Orig1s000SumR.pdf
125486,Gazyva,obinutuzumab,O43472U9X8,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486,9/1/2007,,https://clinicaltrials.gov/ct2/show/NCT00517530,4/22/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/1/2013,2253,193,,1,,1,1,,,1,,,,,,,,,For use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).,
203137,Vizamyl,flutemetamol F-18,L49M066S0O,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203137,10/24/2007,,https://www.ema.europa.eu/en/documents/assessment-report/vizamyl-epar-public-assessment-report_en.pdf,10/26/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/25/2013,2193,364,,,,,,,,,1,,CNC1=C([18F])C=C(C=C1)C2=NC3=C(S2)C=C(O)C=C3,3.39689707,,Alzheimer's disease diagnostic,Binding Agent,Amyloid beta A4 protein,A radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia.,
204410,Opsumit,macitentan,Z9K9Y9WMVL,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204410,7/1/2004,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000ClinPharmR.pdf,10/19/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/18/2013,3396,364,,1,,,,,,,,,CCCNS(=O)(=O)NC1=NC=NC(OCCOC2=NC=C(Br)C=N2)=C1C3=CC=C(Br)C=C3,3.75482496,,,Antagonist,Endothelin B receptor|Endothelin-1 receptor,"To treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.",
204819,Adempas,riociguat,RU3FE2Y4XI,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204819,3/22/2007,,https://www.federalregister.gov/documents/2016/04/12/2016-08337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adempas,2/8/2013,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/8/2013,2392,242,1,1,,,1,,,1,,,COC(=O)N(C)C1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=CC=N4,2.78984986,,,Agonist,Soluble guanylate cyclase,To treat adults with two forms of pulmonary hypertension.,
22247,Duavee,bazedoxifene,Q16TT9C5BK,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022247,3/15/1998,,https://www.federalregister.gov/documents/2018/01/31/2018-01894/determination-of-regulatory-review-period-for-purposes-of-patent-extension-duavee,10/3/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/3/2013,5681,365,,,,,,,,1,,,CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C4=C1C=C(O)C=C4)C5=CC=C(O)C=C5,6.06350998,,,Modulator,Estrogen receptor|Estrogen receptor beta,To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause.,
204447,Brintellix,vortioxetine,3O2K1S3WQV,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204447,5/4/2007,,https://www.federalregister.gov/documents/2016/04/04/2016-07477/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brintellix,10/2/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/30/2013,2341,363,,,,,,,,1,,,CC1=CC(C)=C(SC2=C(C=CC=C2)N3CCNCC3)C=C1,4.75986374,,,Antagonist,5-hydroxytryptamine receptor 1A|5-hydroxytryptamine receptor 1B|5-hydroxytryptamine receptor 1D|5-hydroxytryptamine receptor 3A|5-hydroxytryptamine receptor 7,To treat adults with major depressive disorder.,
204790,Tivicay,dolutegravir,DKO1W9H7M1,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204790,10/24/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1s000MedR.pdf,12/17/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/12/2013,2119,238,,,1,,1,,,,,,C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12,1.12523129,,,Inhibitor,UNIPROT: Q7ZJM1,To treat HIV-1 infection.,
201292,Gilotrif,afatinib,41UD74L59M,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292,1/30/2004,,https://www.federalregister.gov/documents/2018/02/12/2018-02767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilotrif,11/15/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/12/2013,3451,239,,1,1,,1,,,,,,CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C3N=CN=C(NC4=CC(Cl)=C(F)C=C4)C3=C1,3.83641069,,,Antagonist,Epidermal growth factor receptor|Receptor tyrosine-protein kinase erbB-2|Receptor tyrosine-protein kinase erbB-4,"For patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.",
204114,Mekinist,trametinib,33E86K87QN,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204114,5/15/2008,,https://www.federalregister.gov/documents/2016/06/01/2016-12859/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mekinist,8/3/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/29/2013,1840,299,1,1,1,,,,,,,,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC4=C(F)C=C(I)C=C4)C5=CC(NC(C)=O)=CC=C5,2.97485664,,,Antagonist,Dual specificity mitogen-activated protein kinase kinase 1|Dual specificity mitogen-activated protein kinase kinase 2,To treat patients whose tumors express the BRAF V600E or V600K gene mutations.,
202806,Tafinlar,dabrafenib,QGP4HA4G1B,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,7/24/2009,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf,7/30/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/29/2013,1405,303,,1,1,,,,,,,,CC(C)(C)C1=NC(=C(S1)C2=NC(N)=NC=C2)C3=C(F)C(NS(=O)(=O)C4=C(F)C=CC=C4F)=CC=C3,5.43941666,,,Inhibitor,Serine/threonine-protein kinase B-raf,To treat patients with melanoma whose tumors express the BRAF V600E gene mutation.,
203971,Xofigo,radium Ra 223 dichloride,RJ00KV3VTG,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203971,8/14/2001,,https://www.clinicaltrials.gov/ct2/show/NCT01798108,12/14/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/15/2013,4292,152,1,,1,,1,,,,,,[223Ra++],0,,,,,To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.,
204275,Breo Ellipta,vilanterol,028LZY775B,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204275,12/10/2007,,https://www.federalregister.gov/documents/2016/02/22/2016-03551/determination-of-regulatory-review-period-for-purposes-of-patent-extension-breo-ellipta,7/12/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/10/2013,1978,302,,,,,,,,,,,OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl,3.76473471,,,Agonist,"adrenoceptor beta 2, surface","For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.",
204042,Invokana,canagliflozin,0SAC974Z85,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204042,11/15/2006,,https://www.pmda.go.jp/drugs/2014/P201400070/400315000_22600AMX00744_K105_1.pdf,5/31/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/29/2013,2326,302,1,,,,,,,,,,CC1=C(CC2=CC=C(S2)C3=CC=C(F)C=C3)C=C(C=C1)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O,3.51165755,,,Inhibitor,Sodium/glucose cotransporter 2,"Used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.",
204063,Tecfidera,dimethyl fumarate,FO2303MNI2,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204063,NA,Ex-US clinical development predates IND,https://www.federalregister.gov/documents/2017/10/05/2017-21435/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecfidera,2/27/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/27/2013,NA,394,1,,,,,,,,,,COC(=O)\C=C\C(=O)OC,0.63003948,,,,,To treat adults with relapsing forms of multiple sclerosis (MS).,
125462,BAT,equine botulinum neurotoxin A-G immune fab2,X5I2P7E9TY|30Y9N0SEBE|T95649SUV7|RJN8G983LQ|943578J0XG,Antibacterial,protein,antibody,antibody,BLA,https://wayback.archive-it.org/7993/20170722071334/https:/www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm345134.htm,7/1/2006,,https://clinicaltrials.gov/ct2/show/NCT00360737,9/20/2012,https://wayback.archive-it.org/7993/20170723024133/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM358262.pdf,3/22/2013,2456,183,,1,,,1,,,,,1,,,,,,,Patients with documented or suspected symptomatic botulism poisoning,
204781,Dotarem,gadoterate meglumine,L0ND3981AG,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,6/12/2002,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204781Orig1s000MedR.pdf,9/20/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/20/2013,3934,181,,,,,1,,,1,1,,OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,-6.0834126,,,,,"For use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.",
202207,Lymphoseek,technetium Tc 99m tilmanocept,8IHI69PQTC,Oncology,polymer,polymer,polymer,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202207,2/28/2001,,https://www.federalregister.gov/documents/2018/02/22/2018-03610/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lymphoseek,8/10/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/13/2013,4396,581,,,,,,,1,,1,,,,,breast cancer diagnostic,Binding Agent,Macrophage mannose receptor 1,A radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202207Orig1s000SumR.pdf
203505,Osphena,ospemifene,B0P231ILBK,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203505,5/7/2003,,https://www.federalregister.gov/documents/2016/06/01/2016-12823/determination-of-regulatory-review-period-for-purposes-of-patent-extension-osphena,4/26/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/26/2013,3583,306,,,,,,,,,,,OCCOC1=CC=C(C=C1)C(=C(\CCCl)C2=CC=CC=C2)\C3=CC=CC=C3,5.4550844,,,Modulator,Estrogen receptor|Estrogen receptor beta,"To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.",
125427,Kadcyla,ado-trastuzumab emtansine,SE2KH7T06F,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427,1/18/2006,,https://www.federalregister.gov/documents/2015/12/28/2015-32475/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kadcyla,8/27/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/22/2013,2592,179,1,,1,,1,,,1,,,,,3rd antibody-drug conjugate to win FDA approval,,Blocker,Receptor tyrosine-protein kinase erbB-2,"For patients with HER2-positive, late-stage (metastatic) breast cancer.",
204026,Pomalyst,pomalidomide,D2UX06XLB5,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204026,12/9/2002,,https://www.federalregister.gov/documents/2016/06/10/2016-13796/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pomalyst,4/10/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/8/2013,3714,304,,1,1,,,1,,1,,,NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1,-0.1571866,,,Inhibitor,tumor necrosis factor,To treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.,
203568,Kynamro,mipomersen sodium,18EAY4870E,Endocrinology,oligonucleotide,oligo,antisense oligo,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203568,12/18/2005,,https://www.federalregister.gov/documents/2015/04/24/2015-09522/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kynamro,3/29/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/29/2013,2599,306,1,1,,,,,,1,,,,,First antisense drug approved,,,,To treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH).,
22271,Nesina,alogliptin,JHC049LO86,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022271,10/20/2004,,https://www.federalregister.gov/documents/2015/05/04/2015-10337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nesina,12/27/2007,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/25/2013,3019,1856,,,,,,,1,,,,CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O,1.03208928,,,Inhibitor,Dipeptidyl peptidase 4,To improve blood sugar control in adults with type 2 diabetes.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000OtherActionLtr.pdf
202292,Fulyzaq,crofelemer,PY79D6C8RX,Other Infectious disease,polymer,polymer,polymer,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202292,9/11/1991,,https://www.federalregister.gov/documents/2015/12/10/2015-31097/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fulyzaq,12/5/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/31/2012,7782,392,1,,1,,1,,,,,,,,,diarrhea in HIV/AIDS patients,Inhibitor,Anoctamin-1|Cystic fibrosis transmembrane conductance regulator,"To treat HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite.",
202155,Eliquis,apixaban,3Z9Y7UWC1J,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202155,11/28/2002,,https://www.federalregister.gov/documents/2015/12/10/2015-31096/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eliquis,9/28/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/28/2012,3683,457,,,1,,1,,1,,,,COC1=CC=C(C=C1)N2N=C(C(N)=O)C3=C2C(=O)N(CC3)C4=CC=C(C=C4)N5CCCCC5=O,1.85860065,,,Inhibitor,Coagulation factor X,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000OtherActionLtrs.pdf
204384,Sirturo,bedaquiline,78846I289Y,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204384,12/9/2006,,https://www.federalregister.gov/documents/2015/12/10/2015-31098/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sirturo,6/29/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/28/2012,2211,182,1,1,1,,1,1,,,,,COC1=C(C=C2C=C(Br)C=CC2=N1)[C@@H](C3=CC=CC=C3)[C@@](O)(CCN(C)C)C4=C5C=CC=CC5=CC=C4,7.17363432,First new drug for tuberculosis in 40 years,tuberculosis,Inhibitor,ATP synthase subunit c,As part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available.,
203441,Gattex,teduglutide,7M19191IKG,Gastroenterology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203441,5/27/1999,,https://www.federalregister.gov/documents/2015/05/07/2015-11000/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gattex,11/30/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/21/2012,4957,387,1,1,,,,,,,,,,,,,Agonist,Glucagon-like peptide 2 receptor,To treat adults with short bowel syndrome (SBS) who need additional nutrition from intravenous feeding (parenteral nutrition).,
203858,Juxtapid,lomitapide,82KUB0583F,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203858,7/18/1996,,https://www.federalregister.gov/documents/2015/04/06/2015-07809/determination-of-regulatory-review-period-for-purposes-of-patent-extension-juxtapid,2/29/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/21/2012,6000,296,1,1,,,,,,1,,,FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=C(C=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C5=CC=CC=C5C6=C4C=CC=C6,7.90894575,,,Inhibitor,Microsomal triglyceride transfer protein large subunit,"To reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH).",
125349,raxibacumab,raxibacumab,794PGL549S,Antibacterial,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125349,6/22/2003,,https://www.federalregister.gov/documents/2015/12/15/2015-31400/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raxibacumab,5/14/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/14/2012,3463,1310,1,1,1,,1,,1,,,1,,,,,,,"To treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125349Orig1s000SumR.pdf
200677,Signifor,pasireotide,98H1T17066,Endocrinology,chemical,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200677,7/17/2003,,https://www.federalregister.gov/documents/2015/05/07/2015-10994/determination-of-regulatory-review-period-for-purposes-of-patent-extension-signifor,2/17/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/14/2012,3438,301,1,1,,,,,,,,,,,,,Agonist,Somatostatin receptor 1|Somatostatin receptor 2|Somatostatin receptor 3|Somatostatin receptor 5,To treat Cushing disease patients who cannot be helped through surgery,
203469,Iclusig,ponatinib,4340891KFS,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469,11/21/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000MedR.pdf,9/27/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,12/14/2012,1850,78,,1,1,,1,1,,,,,CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2)C(F)(F)F)CC1,4.98710736,,,Inhibitor,Breakpoint cluster region protein|Tyrosine-protein kinase ABL1,"To treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.",
203756,Cometriq,cabozantinib,1C39JW444G,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203756,7/13/2005,,https://www.federalregister.gov/documents/2015/04/22/2015-09302/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cometriq,5/29/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/29/2012,2696,184,,1,1,,1,,,1,,,COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3)=CC=NC2=C1,4.66774436,,,Inhibitor,Hepatocyte growth factor receptor|Proto-oncogene tyrosine-protein kinase receptor Ret|Vascular endothelial growth factor receptor 2,To treat medullary thyroid cancer that has spread to other parts of the body (metastasized).,
203214,Xeljanz,tofacitinib,87LA6FU830,Rheumatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203214,1/18/2002,,https://www.federalregister.gov/documents/2015/06/12/2015-14433/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xeljanz,10/21/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/6/2012,3945,382,,,,,,,,1,,,C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,1.26078954,,,Inhibitor,Tyrosine-protein kinase JAK1|Tyrosine-protein kinase JAK2|Tyrosine-protein kinase JAK3,"To treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.",
203585,Synribo,omacetaxine mepesuccinate,6FG8041S5B,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203585,5/17/2001,,https://www.federalregister.gov/documents/2015/05/07/2015-11004/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synribo,3/30/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/26/2012,4180,210,1,1,1,,,1,,,,,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2C3=C(CCN4CCC[C@]24C=C1OC)C=C5OCOC5=C3,2.08153507,,,Antagonist,60S ribosomal protein L3,"To treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf
202834,Fycompa,perampanel,H821664NPK,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202834,11/7/2003,,https://www.federalregister.gov/documents/2016/09/23/2016-22933/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fycompa,12/22/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/22/2012,3272,305,1,,,,,,,1,,,O=C1N(C=C(C=C1C2=C(C=CC=C2)C#N)C3=NC=CC=C3)C4=CC=CC=C4,3.96794696,,,Antagonist,Glutamate receptor ionotropic AMPA,To treat partial onset seizures in patients with epilepsy ages 12 years and older.,
125422,Jetrea,ocriplasmin,7V6HE3DM5A,Opthamology,protein,peptide,peptide,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125422,11/9/2006,,https://www.federalregister.gov/documents/2015/12/23/2015-32247/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jetrea,4/17/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/17/2012,2169,183,1,,,,1,,,,,,,,,,,,To treat an eye condition called symptomatic vitreomacular adhesion (VMA).,
203085,Stivarga,regorafenib,24T2A1DOYB,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085,8/18/2006,,https://www.federalregister.gov/documents/2015/05/22/2015-12577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stivarga,4/27/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/27/2012,2232,153,,,1,,1,,,1,,,CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,4.45285514,,,Inhibitor,Proto-oncogene tyrosine-protein kinase receptor Ret|RAF proto-oncogene serine/threonine-protein kinase|Vascular endothelial growth factor receptor 2,To treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).,
203155,Choline C 11 Injection,choline C-11,M4AS4XGD4Q,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203155Orig1s000SumR.pdf,12/12/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/12/2012,NA,275,,,,,1,,,,1,,C[N+](C)([11CH3])CCO,-4.2003121,,,,,A Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.,
202992,Aubagio,teriflunomide,1C058IKG3B,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202992,8/27/2004,,https://www.federalregister.gov/documents/2015/04/15/2015-08615/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aubagio-patent-no-5679709,8/12/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/12/2012,2938,397,,,,,,,,1,,,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,2.13617165,,,,,For the treatment of adults with relapsing forms of multiple sclerosis (MS).,
203341,Bosulif,bosutinib,5018V4AEZ0,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341,5/19/2004,,https://www.federalregister.gov/documents/2015/05/04/2015-10333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bosulif,11/17/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/4/2012,3030,292,,1,,,,,,,,,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,4.17216116,,,Inhibitor,Proto-oncogene tyrosine-protein kinase Src|Tyrosine-protein kinase ABL1,"To treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.",
203415,Xtandi,enzalutamide,93T0T9GKNU,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203415,6/29/2007,,https://www.federalregister.gov/documents/2015/12/18/2015-31824/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xtandi,5/22/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/31/2012,1890,101,,,1,,1,,,,,,CNC(=O)C1=C(F)C=C(C=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F,4.17568505,,,Inhibitor,Androgen Receptor,"To treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.",
202811,Linzess,linaclotide,N0TXR0XR5X,Gastroenterology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202811,10/30/2004,,https://www.federalregister.gov/documents/2014/05/23/2014-11926/determination-of-regulatory-review-period-for-purposes-of-patent-extension-linzess,8/9/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/30/2012,2861,387,1,,,,,,,1,,,,,,,Agonist,Heat-stable enterotoxin receptor,To treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.,
125294,Granix,tbo-filgrastim,PVI5M0M1GW,Oncology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125294,NA,Biosimilar,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125294Orig1s000MedR.pdf,11/30/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/29/2012,NA,1003,,,,,,,1,,,,,,,,,,"To reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125294Orig1s000CrossR.pdf
203100,Stribild,elvitegravir|cobicistat,4GDQ854U53|LW2E03M5PG,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203100,4/18/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203094Orig1Orig2s000MedR.pdf,10/27/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/27/2012,2688,305,,,1,,,,,1,,,COC1=CC2=C(C=C1CC3=C(F)C(Cl)=CC=C3)C(=O)C(=CN2[C@H](CO)C(C)C)C(O)=O,4.72614495,,,Inhibitor,Human immunodeficiency virus type 1 integrase,A once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.,
125418,Zaltrap,ziv-aflibercept,15C2VL427D,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125418_zaltrap_toc.cfm,8/2/2001,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125418Orig1s000SumR.pdf,2/3/2012,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/3/2012,4019,182,,,,,1,,,1,,,,,,,,,"For use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.",
202450,Tudorza Pressair,aclidinium bromide,UQW7UF9N91,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202450,12/24/2003,,https://www.federalregister.gov/documents/2015/05/04/2015-10336/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tudorza-pressair,6/23/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/23/2012,3134,396,,,,,,,,,,,OC(C(=O)O[C@H]1C[N+]3(CCCOC2=CC=CC=C2)CCC1CC3)(C4=CC=CS4)C5=CC=CS5,1.02076455,,,Antagonist,Muscarinic acetylcholine receptor M3,"For the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
202714,Kyprolis,carfilzomib,72X6E3J5AR,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202714,7/14/2005,,https://www.federalregister.gov/documents/2014/05/15/2014-11175/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kyprolis,9/27/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/20/2012,2563,297,,1,1,,,1,,,,,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,4.25562305,,,Inhibitor,26S proteosome,"To treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory.",
202535,Prepopik,sodium picosulfate,LR57574HN8,Gastroenterology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202535_prepopik_toc.cfm,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202535Orig1s000PharmR.pdf,9/16/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/16/2012,NA,304,,,,,,,,,,,[O-]S(=O)(=O)OC1=CC=C(C=C1)C(C2=CC=C(OS([O-])(=O)=O)C=C2)C3=NC=CC=C3,-0.9016134,,,Binding Agent,colonic mucosa,To help cleanse the colon in adults preparing for colonoscopy.,
202611,Myrbetriq,mirabegron,MVR3JL3B2V,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202611,6/9/2006,,https://www.federalregister.gov/documents/2014/05/28/2014-12292/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myrbetriq,8/29/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/28/2012,2211,304,1,,,,,,,,,,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,2.91638603,,,Agonist,Beta-3 adrenergic receptor,To treat adults with overactive bladder.,
22529,Belviq,lorcaserin hydrochloride,0QJF08GDPE,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022529,6/23/2004,,https://www.federalregister.gov/documents/2016/09/23/2016-22937/determination-of-regulatory-review-period-for-purposes-of-patent-extension-belviq,12/22/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/27/2012,2926,918,1,,,,,,1,,,,C[C@H]1CNCCC2=CC=C(Cl)C=C12,2.86765237,,,Agonist,Serotonin 2c (5-HT2c) receptor,For chronic weight management.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000OtherR.pdf
125409,Perjeta,pertuzumab,K16AIQ8CTM,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,9/11/2001,,https://www.federalregister.gov/documents/2014/05/19/2014-11515/determination-of-regulatory-review-period-for-purposes-of-patent-extension-perjeta,12/8/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/8/2012,3923,183,,,,,1,,,1,,,,,,,,,To treat patients with HER2-positive late-stage (metastatic) breast cancer.,
22458,Elelyso,taliglucerase alfa,0R4NLX88O4,Endocrinology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458,7/16/2005,,https://www.federalregister.gov/documents/2014/05/19/2014-11516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elelyso,4/26/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/1/2012,2481,736,,1,1,,,,1,,,,,,,,,,"For long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022458Orig1s000Admincorres.pdf
202276,Stendra,avanafil,DR5S136IVO,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202276,1/2/2002,,https://www.federalregister.gov/documents/2014/06/10/2014-13444/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stendra,6/29/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/27/2012,3768,303,,,,,,,,,,,COC1=C(Cl)C=C(CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)C=C1,2.81398468,,,Inhibitor,Phosphodiesterase 5A,To treat erectile dysfunction.,
202008,Amyvid,florbetapir F 18,6W15Z5R0RU,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202008_Florbetapir_Orig1s000TOC.cfm,3/6/2008,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202008Orig1s000MedR.pdf,9/17/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/6/2012,1492,567,1,,,,1,,1,,1,,CNC1=CC=C(\C=C\C2=CN=C(OCCOCCOCC[18F])C=C2)C=C1,3.09415021,,Alzheimer's disease diagnostic,,,Used as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate alpha-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer Disease (AD) and other causes of cognitive decline.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202008Orig1s000SumR.pdf
202799,Omontys,peginesatide,JX56W9N61Q,Hematology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202799_Omontys_Orig1s000TOC.cfm,8/1/2004,,https://clinicaltrials.gov/ct2/show/NCT00097747,5/27/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/27/2012,2795,305,,,,,,,,1,,,,,,,Activator,Erythropoietin receptor,"To treat anemia, a condition in which the body does not have enough healthy red blood cells, in adult dialysis patients who have chronic kidney disease (CKD).",
21746,Surfaxin,sinapultide,040X3AX99T,Respiratory,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021746,9/5/1992,,https://www.federalregister.gov/documents/2014/05/13/2014-10904/determination-of-regulatory-review-period-for-purposes-of-patent-extension-surfaxin,4/13/2004,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/6/2012,7122,2884,,,1,,,,1,,,,,,,,,,"For the prevention of respiratory distress syndrome (RDS), a breathing disorder that affects premature infants.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021746Orig1s000SumR.pdf
202514,Zioptan,tafluprost,1O6WQ6T7G3,Opthamology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202514,6/28/2001,,https://www.federalregister.gov/documents/2014/05/19/2014-11517/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zioptan,1/7/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/10/2012,3879,399,,,,,,,,,,,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC2=CC=CC=C2,4.27753181,,,Agonist,Prostanoid FP receptor,For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.,
203188,Kalydeco,ivacaftor,1Y740ILL1Z,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203188,4/13/2006,,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,10/18/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/31/2012,2119,105,1,1,1,,1,,,,,,CC(C)(C)C1=CC(=C(NC(=O)C2=CNC3=C(C=CC=C3)C2=O)C=C1O)C(C)(C)C,5.70557069,First medicine to treat the underlying cause of cystic fibrosis,,Activator,Cystic fibrosis transmembrane conductance regulator,For the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.,
203388,Erivedge,vismodegib,25X868M3DS,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203388,11/3/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203388Orig1s000MedRpdf.pdf,9/8/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/30/2012,1914,144,1,,,,1,,,1,,,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC2=CC(=C(Cl)C=C2)C3=NC=CC=C3,3.94639701,,,Antagonist|Inhibitor,Smoothened homolog,"To treat adult patients with basal cell carcinoma, the most common type of skin cancer.",
202324,Inlyta,axitinib,C9LVQ0YUXG,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202324,12/13/2001,,https://www.federalregister.gov/documents/2014/05/23/2014-11925/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inlyta,4/14/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/27/2012,3697,288,,,1,,,,,,,,CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\C=C\C4=NC=CC=C4)=NN3)C=CC=C1,4.02217218,,,,,To treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.,
202833,Picato,ingenol mebutate,7686S50JAH,Dermatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202833,7/28/2004,,https://www.federalregister.gov/documents/2014/05/20/2014-11521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-picato,3/25/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/23/2012,2735,304,1,,,,,,,,,,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,2.39718762,,,,,For the topical treatment of actinic keratosis.,
125327,Voraxaze,glucarpidase,2GFP9BJD79,Hematology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125327,8/7/1992,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125327Orig1s000SumR.pdf,7/18/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/17/2012,7102,183,1,1,1,,1,,,,,,,,,,Hydrolytic Enzyme,Methotrexate,To treat patients with toxic levels of methotrexate in their blood due to kidney failure.,
125359,Erwinaze,asparaginase Erwinia chrysanthemi,D733ET3F9O,Oncology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125359_erwinaze_toc.cfm,4/1/1968,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125359Orig1s000MedR.pdf,11/1/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/18/2011,15936,382,,1,1,,1,,,,,,,,,Acute lymphoblastic leukemia,,asparaginase,ERWINAZE (asparaginase Erwinia chrysanthemi) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.,
125387,Eylea,aflibercept,15C2VL427D,Oncology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387s0000TOC.cfm,6/15/2005,,https://www.federalregister.gov/documents/2014/04/02/2014-07333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eylea,2/18/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/18/2011,2347,273,,,,,1,,,,,,,,,Age-related macular degeneration,,"receptors, vascular endothelial growth factor",EYLEA is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD).,
202192,Jakafi,ruxolitinib,82S8X8XX8H,Rheumatology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202192,3/30/2007,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf,6/3/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/16/2011,1692,166,1,1,1,,1,,,,,,N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4,2.57672391,,Myelofibrosis,,janus kinase,"Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.",
125397,Hemacord,human cord blood hematopoietic progenitor cell,XU53VK93MC,Hematology,cell,cell,cell,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/hemacord-hpc-cord-blood,5/29/1996,,https://www.fda.gov/media/82073/download,1/10/2011,https://www.fda.gov/media/82073/download,11/10/2011,5643,304,,,,,,,,,,,,,,Allogeneic cord blood hematopoietic progenitor cell therapy,,,Allogeneic cord blood hematopoietic progenitor cell therapy,
202067,Onfi,clobazam,2MRO291B4U,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202067,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf,12/23/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/21/2011,NA,302,,1,,,,,,,,,CN1C2=C(C=C(Cl)C=C2)N(C3=CC=CC=C3)C(=O)CC1=O,2.5352748,,Lennox-Gastaut syndrome,,,ONFI (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.,
21825,Ferriprox,deferiprone,2BTY8KH53L,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021825,NA,Ex-US clinical development predates IND,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000MedR.pdf,1/30/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/14/2011,NA,987,,1,1,,,1,1,1,,,CN1C=CC(=O)C(O)=C1C,0.60570424,,Transfusional iron overload,,for the treatment of patients with transfusional iron overload,FERRIPROX (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000SumR.pdf
202570,Xalkori,crizotinib,53AH36668S,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,1/12/2006,,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,3/30/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/26/2011,2052,149,1,1,1,,1,1,,,,,C[C@@H](OC1=C(N)N=CC(=C1)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C(F)=CC=C4Cl,3.62884885,,Non-small cell lung cancers (NSCLC),,anaplastic lymphoma kinase,XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.,
22150,Firazyr,icatibant,7PG89G35Q7,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022150_firazyr_toc.cfm,5/12/2004,,https://www.federalregister.gov/documents/2014/04/02/2014-07331/determination-of-regulatory-review-period-for-purposes-of-patent-extension-firazyr,10/26/2007,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/25/2011,2661,1399,1,1,1,,1,,1,,,,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5,-7.6016747,,Hereditary angioedema (HAE),,bradykinin receptor B2,FIRAZYR (icatibant) is indicated for the treatment of acute attacts of hereditary angioedema (HAE) in adults 18 years of age and older.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022150Orig1s000AdminCorres.pdf
125388,Adcetris,brentuximab vedotin,7XL5ISS668,Oncology,protein,antibody,antibody-drug conjugate,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388_adcetris_toc.cfm,6/27/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000MedR.pdf,2/28/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/19/2011,1879,172,1,1,1,,1,1,,,,,,,,Hodgkin’s lymphoma and ALCL (systemic anaplastic large cell lymphoma),,cd30,ADCETRIS (brentuximab vedotin) is indicated for treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates. ADCETRIS is indicated for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.,
202429,Zelboraf,vemurafenib,207SMY3FQT,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429s000TOC.cfm,9/1/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000MedR.pdf,4/28/2011,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/17/2011,1811,111,1,1,1,,1,,,,,,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(Cl)C=C4)=C(F)C=C1,4.61764274,,Prostate cancer,,braf,ZELBORAF is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test.,
125335,Anascorp,scorpion (centruroides) immune fab2 antivenin (equine),DDA050FCEA,Emergency Medicine,protein,antibody,antibody,BLA,https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/anascorp,NA,Original IND submission date not provided,https://web.archive.org/web/20170723145859/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270159.pdf,1/22/2009,https://wayback.archive-it.org/7993/20170723030046/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270465.pdf,8/3/2011,NA,923,,1,,,1,,1,,,,,,,Scorpion envenomation,,,Scorpion envenomation,https://wayback.archive-it.org/7993/20170723030046/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270465.pdf
22433,Brilinta,ticagrelor,GLH0314RVC,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022433,5/29/2003,,https://www.federalregister.gov/documents/2014/04/30/2014-09772/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brilinta,11/16/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/20/2011,2974,611,,,,,,,1,1,,,CCCSC1=NC2=C(N=NN2[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C(N[C@@H]4C[C@H]4C5=CC(F)=C(F)C=C5)=N1,2.31841841,,Acute coronary syndromes (ACS),,p2y receptor,"BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433orig1s000medr.pdf
22383,Arcapta,indacaterol,8OR09251MQ,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022383,1/9/2003,,https://www.federalregister.gov/documents/2014/06/12/2014-13638/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arcapta-neohaler,12/18/2008,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/1/2011,3095,925,,,,,,,1,1,,,CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3,3.63646678,,Chronic obstructive pulmonary disease (COPD),,beta-2-adrenergic receptor,"ARCAPTA NEOHALER is a long-acting beta2-agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000Approv.pdf
22406,Xarelto,rivaroxaban,9NDF7JZ4M3,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022406,6/29/2002,,https://www.federalregister.gov/documents/2014/05/29/2014-12349/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xarelto,7/28/2008,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/1/2011,3289,1068,,,,,,,1,1,,,ClC1=CC=C(S1)C(=O)NC[C@H]2CN(C(=O)O2)C3=CC=C(C=C3)N4CCOCC4=O,1.91495397,,Reduce risk of blot clots,,coagulation factor X,"XARELTO (rivaroxaban) Tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000SumR.pdf
125288,Nulojix,belatacept,E3B2GI648A,Immunology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125288,3/13/1999,,https://www.federalregister.gov/documents/2014/03/31/2014-07060/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nulojix,7/1/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/15/2011,4477,714,1,1,1,,,,1,1,,,,,,Prevent organ transplant rejection,,cytotoxic T-lymphocyte-associated protein 4,"NULOJIX (belatacept) is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. NULOJIX is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125288Orig1s000Ltr.pdf
22345,Potiga,ezogabine,12G01I6BBU,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022345,9/12/1997,,https://www.federalregister.gov/documents/2014/04/02/2014-07334/determination-of-regulatory-review-period-for-purposes-of-patent-extension-potiga,10/30/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/10/2011,5019,588,,,,,,,1,,,,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,2.63067424,,Epilepsy,,potassium voltage-gated channel,POTIGA is indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000SumR.pdf
201699,Dificid,fidaxomicin,Z5N076G8YQ,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201699,8/20/2003,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201699Orig1s000StatR.pdf,11/30/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/27/2011,2837,178,,,1,,1,,,,,,CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(C)\C=C(C)\[C@@H]1O[C@@H]4OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]4O)[C@@H](C)O,8.65941414,,Clostridium difficile-associated diarrhea,,bacterial RNA polymerase,"To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile.",
201917,Incivek,telaprevir,655M5O3W0U,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201917,11/29/2005,,https://www.federalregister.gov/documents/2014/05/20/2014-11525/determination-of-regulatory-review-period-for-purposes-of-patent-extension-incivek,11/23/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/23/2011,2001,181,,,1,,1,,,,,,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5,2.5660377,,Hepatitis C infection,,HCV NS3,"INCIVEK (telaprevir), in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based treatment, including prior null responders, partial responders, and relapsers.",
202022,Edurant,rilpivirine,FI96A8X663,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202022,10/29/2004,,https://www.federalregister.gov/documents/2014/05/01/2014-09911/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edurant,7/23/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/20/2011,2394,301,,,,,,,,,,,CC1=CC(\C=C\C#N)=CC(C)=C1NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2,5.54822255,,HIV-1 infection,,gag pol hiv,"EDURANT, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients.",
202258,Victrelis,boceprevir,89BT58KELH,Antiviral,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202258,6/15/2005,,https://www.federalregister.gov/documents/2014/06/27/2014-15021/determination-of-regulatory-review-period-for-purposes-of-patent-extension-victrelis,11/15/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/13/2011,2158,179,1,,1,,1,,,,,,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C,1.70084559,,Hepatitis C infection,,HCV NS3,"VICTRELIS (boceprevir) is indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.",
201280,Tradjenta,linagliptin,3X29ZEJ4R2,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201280,9/21/2005,,https://www.federalregister.gov/documents/2014/05/13/2014-10945/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tradjenta,7/2/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/2/2011,2049,304,,,,,,,,,,,CC#CCN1C(=NC2=C1C(=O)N(CC3=NC4=C(C=CC=C4)C(C)=N3)C(=O)N2C)N5CCC[C@@H](N)C5,2.84549961,,Diabetes,,dipeptidyl-peptidase 4,TRADJENTA tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,
202379,Zytiga,abiraterone,G819A456D0,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202379,1/19/2006,,https://www.federalregister.gov/documents/2013/02/28/2013-04645/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zytiga,12/20/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/28/2011,1925,129,1,,,,1,,,,,,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5,3.82445839,,Prostate cancer,,CYP17A1,ZYTIGA in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.,
22399,Horizant,gabapentin enacarbil,75OCL1SPBQ,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022399,1/12/2005,,https://www.federalregister.gov/documents/2014/07/11/2014-16237/determination-of-regulatory-review-period-for-purposes-of-patent-extension-horizant,1/9/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/6/2011,2275,817,,,,,,,1,,,,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1,2.77950465,,Restless legs syndrome (RLS),,voltage gated calcium channel,HORIZANT (gabapentin enacarbil) Extended-Release Tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000MedR.pdf
22405,Caprelsa,vandetanib,YO460OQ37K,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022405,4/16/2000,,https://www.federalregister.gov/documents/2014/06/11/2014-13566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vandetanib,7/7/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,4/6/2011,4007,273,,1,1,,1,,,1,,,COC1=C(OCC2CCN(C)CC2)C=C3N=CN=C(NC4=C(F)C=C(Br)C=C4)C3=C1,4.6441188,,Medullary thyroid cancer,,vascular endothelial growth factor receptor-2,Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.,
125377,Yervoy,ipilimumab,6T8C155666,Oncology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,8/12/2000,,https://www.federalregister.gov/documents/2014/05/01/2014-09910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yervoy,6/25/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/25/2011,3877,273,1,1,1,,1,,,1,,,,,,Melanoma,,cytotoxic T-lymphocyte-associated protein 4,YERVOY (ipilimumab) is indicated for the treatment of unresectable metastatic melanoma.,
201277,Gadavist,gadobutrol,1BJ477IO2L,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201277,7/8/1999,,https://www.federalregister.gov/documents/2014/01/23/2014-01307/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gadavist,5/14/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/14/2011,4267,304,,,,,,,,1,,,OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,-7.7186377,,Imaging for CNS lesions,,,Gadavast is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.,
125370,Benlysta,belimumab,73B0K5S26A,Rheumatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125370,10/23/2001,,https://www.federalregister.gov/documents/2014/05/15/2014-11176/determination-of-regulatory-review-period-for-purposes-of-patent-extension-benlysta,6/9/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/9/2011,3424,273,1,,1,,1,,,,,,,,,Lupus,,TNFSF13B,"BENLYSTA (belimumab) is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.",
22522,Daliresp,roflumilast,0P6C6ZOP5U,Respiratory,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022522,7/26/1999,,https://www.federalregister.gov/documents/2014/01/23/2014-01306/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daliresp,7/17/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/28/2011,4235,591,1,,,,,,1,,,,FC(F)OC1=CC=C(C=C1OCC2CC2)C(=O)NC3=C(Cl)C=NC=C3Cl,4.57505369,,Chronic obstructive pulmonary disease (COPD),,phosphodiesterase 4,DALIRESP is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000MedR.pdf
200796,Edarbi,azilsartan,F9NUX55P23,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796sOrig1s000_Edarbi_TOC.cfm,4/19/2005,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000OtherR.pdf,4/27/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/25/2011,2138,304,,,,,,,,1,,,CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NOC(=O)N5)C(=CC=C2)C(O)=O,4.9632038,,High blood pressure,,angiotensin II type 1 receptor,Edarbi is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.,
125385,Corifact,factor XIII concentrate (human),F7R0FBC1XD,Hematology,protein,enzyme,enzyme,BLA,https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/corifact,8/1/1991,,https://wayback.archive-it.org/7993/20170722071412/https:/www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm244147.htm,8/18/2010,https://wayback.archive-it.org/7993/20170723024727/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM246670.pdf,2/17/2011,7140,183,,1,1,,1,1,,,,,,,,Congenital Factor XIII deficiency,,,Congenital Factor XIII deficiency,
22567,Viibyrd,vilazodone,S239O2OOV3,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022567,12/24/1997,,https://www.federalregister.gov/documents/2012/04/06/2012-8341/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viibryd,3/22/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/21/2011,4776,305,,,,,,,,1,,,NC(=O)C1=CC2=C(O1)C=CC(=C2)N3CCN(CCCCC4=CNC5=CC=C(C=C45)C#N)CC3,3.65388374,,Major depressive disorder,,"5-ht1a receptor, serotonin reuptake","VIIBRYD is indicated for the treatment of major depressive disorder (MDD). The efficacy of VIIBRYD was established in two 8-week, randomized, double-blind, placebo-controlled trials in adult patients with a diagnosis of MDD.",
22408,Natroba,spinosad,XPA88EAP6V,Other Infectious disease,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022408,11/11/2004,,https://www.federalregister.gov/documents/2012/04/06/2012-8337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natroba,1/22/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/18/2011,2259,726,,,,,,,1,,,,CCC1CCCC(C(C(=O)C2=CC3C4CC(CC4C(=CC3C2CC(=O)O1)C)OC5C(C(C(C(O5)C)OC)OC)OC)C)OC6CCC(C(O6)C)N(C)C,6.05039375,,Head lice,,"receptors, cholinergic",NATROBA (spinosad) Topical Suspension is indicated for the topical treatment of head lice infestation in patients four (4) years of age and older.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022408Orig1s000MedR.pdf
22454,DaTscan,ioflupane I-123,3MM99T8R5Q,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022454,NA,Original IND submission date not provided,https://www.federalregister.gov/documents/2012/04/06/2012-8340/determination-of-regulatory-review-period-for-purposes-of-patent-extension-datscan,3/9/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/14/2011,NA,676,,,,,1,,1,,1,,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC=C([123I])C=C3)N2CCCF,3.77502743,,Imaging for parkinsonian syndrome,,,Imaging for parkinsonian syndrome,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000CrossR.pdf
201532,Halaven,eribulin,LR24G6354G,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201532,4/30/2003,,https://www.federalregister.gov/documents/2012/05/03/2012-10716/determination-of-regulatory-review-period-for-purposes-of-patent-extension-halaven,3/30/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/15/2010,2756,230,,,1,,1,,,,,,CO[C@H]1[C@@H](C[C@H](O)CN)O[C@H]2C[C@H]3O[C@H](C[C@@H](C)C3=C)CC[C@@H]4O[C@H](CC4=C)CC[C@@]56C[C@H]7O[C@@H]8[C@@H](O[C@H]9CC[C@H](CC(=O)C[C@H]12)O[C@@H]9[C@@H]8O5)[C@H]7O6,2.49692677,,Breast cancer,Microtubule inhibitor,microtubule assembly,HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.,
22505,Egrifta,tesamorelin,MQG94M5EEO,Other Infectious disease,protein,protein,protein,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505,11/15/2001,,https://www.federalregister.gov/documents/2012/05/04/2012-10808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-egrifta,5/29/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,11/10/2010,3282,530,1,,,,,,,,,,,,,HIV lipodystrophy,Growth hormone-releasing factor analogue,growth hormone-releasing hormone,EGRIFTA (tesamorelin for injection) is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.,
200327,Teflaro,ceftaroline fosamil,7P6FQA5D21,Antibacterial,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200327,1/12/2005,,https://www.federalregister.gov/documents/2012/04/06/2012-8339/determination-of-regulatory-review-period-for-purposes-of-patent-extension-teflaro,12/30/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/29/2010,2116,303,,,1,,,,,,,,CCO\N=C(/C(=O)N[C@H]1[C@H]2SCC(SC3=NC(=CS3)C4=CC=[N+](C)C=C4)=C(N2C1=O)C(O)=O)C5=NSC(NP(O)([O-])=O)=N5,-3.2311991,,Skin and skin-structure infections; community acquired pneumonia,Broad-spectrum cephalosporin antibiotic,penicillin binding proteins,Teflaro (ceftaroline fosamil) is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms.,
200603,Latuda,lurasidone,22IC88528T,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200603,12/19/2000,,https://www.federalregister.gov/documents/2012/04/06/2012-8354/determination-of-regulatory-review-period-for-purposes-of-patent-extension-latuda,12/30/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/28/2010,3600,302,,,,,,,,1,,,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)C6=NSC7=C6C=CC=C7,4.53720925,,Schizophrenia,Atypical antipsychotic agent,"dopamine receptor, serotonin receptor",LATUDA is indicated for the treatment of patients with schizophrenia.,
22512,Pradaxa,dabigatran,I0VM4M70GC,Cardiology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022512,8/6/2003,,https://www.federalregister.gov/documents/2012/05/03/2012-10712/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pradaxa,4/19/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,10/19/2010,2631,183,1,,,,1,,,,,,CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC3=C1C=CC(=C3)C(=O)N(CCC(O)=O)C4=NC=CC=C4,0.71846736,,Stroke prevention in atrial fibrillation,Direct thrombin inhibitor,thrombin,PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.,
22527,Gilenya,fingolimod,3QN8BYN5QF,Immunology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022527,12/19/1998,,https://www.federalregister.gov/documents/2012/05/04/2012-10819/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilenya,12/21/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/21/2010,4294,274,1,,1,,1,,,,,,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,4.14598607,,Multiple sclerosis,Sphingosine 1-phosphate receptor modulator,"receptors, lysosphingolipid",GILENYA is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.,
125293,Krystexxa,pegloticase,R581OT55EA,Endocrinology,protein,enzyme,PEGlated protein,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125293s0000TOC.cfm,12/19/2001,,https://www.federalregister.gov/documents/2012/05/03/2012-10697/determination-of-regulatory-review-period-for-purposes-of-patent-extension-krystexxa,10/31/2008,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,9/14/2010,3191,683,,1,,,1,,1,1,,,,,,Gout,PEGylated uric acid specific enzyme,urate oxidase,KRYSTEXXA (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125293Orig1s000MedR.pdf
22474,Ella,ulipristal,6J5J15Q2X8,Gynecology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022474s000TOC.cfm,12/1/1995,,https://www.fda.gov/media/83208/download,10/15/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,8/13/2010,5369,302,,,,,,,,,,,CN(C)C1=CC=C(C=C1)[C@H]2C[C@@]3(C)[C@@H](CC[C@]3(O)C(C)=O)[C@@H]4CCC5=CC(=O)CCC5=C24,4.09619411,,Contraception,Progesterone receptor modulator,progesterone receptor,Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.,
125360,Xeomin,incobotulinumtoxina,E211KPY694,Gynecology,protein,protein,protein,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125360s0000TOC.cfm,6/29/2006,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125360s000MedR.pdf,7/2/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/30/2010,1492,393,,,,,,,,1,,,,,,Cervical dystonia and blepharospasm,Acetylcholine release inhibitor and neuromuscular blocking agent,botulinum toxin A,Xeomin (incobotulinumtoxinA) is indicated for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients. XEOMIN (incobotulinumtoxinA) is indicated for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox).,
22134,Lastacaft,alcaftadine,7Z8O94ECSX,Immunology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022134s000TOC.cfm,8/1/2004,,https://www.federalregister.gov/documents/2012/05/03/2012-10694/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lastacaft,9/29/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,7/28/2010,2187,302,,,,,,,,,,,CN1CCC(CC1)=C2C3=NC=C(C=O)N3CCC4=C2C=CC=C4,2.08995485,,Allergic conjunctivitis,H1 histamine receptor antagonist,H1 histamine receptor,LASTACAFT is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.,
201023,Jevtana,cabazitaxel,51F690397J,Oncology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000TOC.cfm,10/30/1998,,https://www.federalregister.gov/documents/2012/05/04/2012-10828/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jevtana,3/31/2010,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/17/2010,4248,78,,,1,,1,,,1,,,CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C,4.33206755,,Prostate cancer,Microtubule inhibitor,microtubule assembly,JEVTANA is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.,
125320,Prolia,denosumab,4EQZ6YO2HI,Endocrinology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320,6/21/2001,,https://www.federalregister.gov/documents/2012/05/07/2012-10959/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prolia,12/19/2008,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,6/1/2010,3267,529,1,,,,,,1,,,,,,,Postmenopausal osteoporosis,Fully human mAb specific for RANKL,tnfsf11,"Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as history of osteoporotic fracture, or multiple risk factors for fracture; or in patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125320s000ODMemo.pdf
125291,Lumizyme,alglucosidase alfa,DTI67O9503,Endocrinology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000TOC.cfm,NA,Biosimilar,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000MedR.pdf,5/30/2008,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/24/2010,NA,724,,1,1,,1,,1,1,,,,,,Pompe's disease,Recombinant human acid α-glucosidase,alpha glucosidase,"LUMIZYME (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for patients 8 years and older with late (non-infantile) onset Pompe disease (acid alpha-glucosidase(GAA) deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of LUMIZYME have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age.",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000MedR.pdf
22252,Natazia,dienogest,46M3EV8HHE,Gynecology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022252,11/17/2004,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1_MedR.pdf,7/6/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,5/6/2010,1996,304,,,,,,,,1,,,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,2.25569108,,Contraception,Oestrogen and progestin combination oral contraceptive,estrogen receptor,Natazia is indicated for use by women to prevent pregnancy.,
125197,Provenge,sipuleucel-T,8Q622VDR18,Oncology,gene therapy,virus,T cell,BLA,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/provenge-sipuleucel-t,12/22/1996,,https://web.archive.org/web/20110328162913/https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM214540.pdf,11/9/2006,https://wayback.archive-it.org/7993/20170723023808/https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM213114.pdf,4/29/2010,4876,1267,1,,1,,1,,1,,,,,,,Prostate cancer,,,Prostate cancer,https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/questions-and-answers-provenge
21201,Asclera,polidocanol,0AWH8BFG9A,Hematology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021201,7/2/1990,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021201s000_Medr.pdf,10/1/1999,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/30/2010,7211,3833,,,,,,,1,,,,CCCCCCCCCCCCOCCO,4.39352315,,Uncomplicated spider veins and uncomplicated reticular veins,Sclerosing agent,,Asclera (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins <=1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extermity. Asclera has not been studied in larger varicose veins more than 3 mm in diameter.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021201s000_PharmR.pdf
22562,Carbaglu,carglumic acid,5L0HB4V1EW,Endocrinology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022562,NA,Original IND submission date not provided,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022562s000crossr.pdf,6/18/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,3/18/2010,NA,273,1,1,1,,1,,,,,,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,-1.5122241,,Acute hyperammonaemia,Carbamoyl phosphate synthetase 1 activator,carbamoyl-phosphate synthase,Carbaglu is indicated as an adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).,
22575,Vpriv,velaglucerase alfa,23HYE36B0I,Endocrinology,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm,1/30/2004,,https://www.federalregister.gov/documents/2011/03/21/2011-6514/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vpriv,8/31/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/26/2010,2219,179,,1,1,,1,,,,,,,,,Gaucher's disease,Recombinant human β-glucocerebrosidase,beta-glucosidase,VPRIV (velaglucerase alfa for injection) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.,
125338,Xiaflex,collagenase Clostridium Histolyticum,9X7O8V25IT,Orthopedics,protein,enzyme,enzyme,BLA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125338,8/24/1995,,https://www.federalregister.gov/documents/2014/06/03/2014-12808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xiaflex,2/27/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,2/2/2010,5276,340,1,1,,,1,,,,,,,,,Dupuytren's contracture,Purified collagenase clostridium histolyticum,microbial collagenase,XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.,
22341,Victoza,liraglutide,839I73S42A,Endocrinology,protein,peptide,peptide,NDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm,11/5/2000,,https://www.federalregister.gov/documents/2012/05/02/2012-10517/determination-of-regulatory-review-period-for-purposes-of-patent-extension-victoza,5/23/2008,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/25/2010,3368,612,,,,,,,,1,,,,,,Type 2 diabetes,Glucagon-like peptide 1 receptor agonist,glucagon-like peptide 1,Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,
22250,Ampyra,dalfampridine,BH3B64OKL9,Neurology,chemical,small molecule,small molecule,NDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022250,2/10/1983,,https://www.federalregister.gov/documents/2011/03/09/2011-5312/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ampyra,4/22/2009,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/22/2010,9843,275,,1,,,1,,,,,,NC1=CC=NC=C1,-0.0874837,,Improving walking in patients with multiple sclerosis,Potassium channel blocker,potassium channel,AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.,
125276,Actemra,tocilizumab,I031V2H011,Rheumatology,protein,antibody,antibody,BLA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000TOC.cfm,11/4/2004,,https://www.federalregister.gov/documents/2011/05/31/2011-13388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actemra,11/19/2007,https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals,1/8/2010,1891,781,1,,,,,,1,1,,,,,,Rheumatoid arthritis,Humanized mAb specific for the interleukin-6 receptor,interleukin 6 receptor,ACTEMRA (tocilizumab) is indicated for treatment of adult patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000MedR.pdf